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Abstract  
 
This article is an update of the requirements of a specialist breast centre, produced by EUSOMA and 
endorsed by ECCO as part of Essential Requirements for Quality Cancer Care (ERQCC) programme, 
and ESMO. 
 
• The centrepiece of this article is the requirements section, comprising definitions; 
multidisciplinary structure; minimum case, procedure and staffing volumes; and detailed 
descriptions of the skills of, and resources needed by, members and specialisms in the 
multidisciplinary team in a breast centre.  
• These requirements are positioned within narrative on European breast cancer epidemiology, 
the standard of care, challenges to delivering this standard, and supporting evidence, to 
enable a broad audience to appreciate the importance of establishing these requirements in 
specialist breast centres.  
To meet aspirations for comprehensive cancer control, healthcare organisations must consider the 
requirements in this article, paying particular attention to multidisciplinarity and patient-centred 
pathways from diagnosis, to treatment, to survivorship. 
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1 INTRODUCTION: THE NEED FOR QUALITY FRAMEWORKS 
There has been a growing emphasis on driving up quality in cancer organisations in order to optimise 
patients outcomes. The European Cancer Concord (ECC), a partnership of patients, advocates and 
cancer professionals, has recognised major disparities in the quality of cancer management and in the 
degree of funding in Europe, and has launched a European Cancer Patient’s Bill of Rights, a patient 
charter that underpins equitable access to optimal cancer control, cancer care and research for 
Europe’s citizens.1  
It follows an assessment of the quality of cancer care in Europe as part of the first EU Joint Action on 
Cancer, the European Partnership for Action Against Cancer (EPAAC, http://www.epaac.eu), which 
reported in 2014 that there are important variations in service delivery between and within countries, 
with repercussions in quality of care. Factors such as waiting times and provision of optimal treatment 
can explain about a third of the differences in cancer survival, while lack of cancer plans, for example 
a national cancer plan that promotes clinical guidelines, professional training and quality control 
measures, may be responsible for a quarter of the survival differences.  
The EU Joint Action on Cancer Control (CANCON), which replaced EPAAC from 2014, also focused 
on quality of cancer care and in 2017 published the European Guide on Quality Improvement in 
Comprehensive Cancer Control.2 This recognised that many cancer patients are treated in general 
hospitals and not in comprehensive cancer centres (CCCs) and explores a model of ‘comprehensive 
cancer care networks’ that can integrate expertise under a single governance structure. Research also 
shows that care provided by multidisciplinary teams (MDTs) result in better clinical and organisational 
outcomes for patients.3 
Countries have been concentrating expertise for certain tumour types in such networks and in 
dedicated centres, or units, such as for childhood and rare cancers, and all CCCs have teams for the 
main cancer types. For common adult tumours, however, at the European level there has been 
widespread effort to establish universal, dedicated units only for breast cancer, following several 
European declarations that set a target of the year 2016 for care of all women and men with breast 
cancer to be delivered in specialist multidisciplinary centres. While this target was not met, as detailed 
in a European Breast Cancer Council manifesto calling for universal breast units,4 the view of the 
ERQCC expert group is that healthcare systems must strive to adopt the principles of such dedicated 
care for all types of cancer. 
 
1.1 Breast cancer 
There is a 20-year history in Europe of calling for, and developing, specialist breast cancer units. In 
the year 2000, the European Society of Breast Cancer Specialists (EUSOMA) published a position 
paper, ‘The requirements of a specialist breast unit’, which was the first to set out standards for 
establishing high-quality breast cancer centres or units across Europe.5 The paper followed a 
consensus statement drawn up at the first European Breast Cancer Conference in Florence in 1998 
that demanded that, ‘Those responsible for organising and funding breast cancer care ensure that all 
women have access to fully equipped multidisciplinary and multiprofessional breast clinics based on 
population numbers of around 250,000.’6 The statement was based on a growing body of evidence 
that optimal care for breast cancer patients can only be obtained by an MDT, preferably based at one 
location. 
In the following years, European Parliament resolutions and declarations have called for universal 
breast cancer units or centres in Europe,7,8 while a number of papers and documents have developed 
quality standards and EUSOMA has refined the requirements,9 which were also included in the 
European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis.10 
This paper is an update of the EUSOMA requirements paper, endorsed by the European CanCer 
Organisation (ECCO) as part of its Essential Requirements for Quality Cancer Care (ERQCC) 
programme, and by the European Society of Medical Oncology (ESMO).  
This update has a wider quality context, adding narrative on epidemiology, challenges in breast cancer 
care, and quality and audit processes and examples, in addition to the components of a breast centre. 
It is based on the changes in organisation and care over the past 5 years as detailed by 
representatives of the disciplines working in breast cancer care. 
The definition of the breast centre (or unit) that applies throughout this paper is: 
 
The place where breast cancer is diagnosed and treated; it has to provide all the services necessary, 
from genetics and prevention, through the treatment of the primary tumour, to care of advanced 
disease, supportive and palliative care and survivorship, and psychosocial support. 
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2. BREAST CANCER: KEY FACTS AND CHALLENGES 
 
2.1 KEY FACTS 
 
2.1.1 Epidemiology 
• Breast cancer is the most common cancer in women in the European Union and a rare cancer 
in men. It comprises a wide range of histopathological subtypes, the most common being 
invasive carcinoma of no special type (NST), previously named invasive ductal carcinoma, 
and invasive lobular carcinoma.11 Much less common are all the other histological subtypes. 
Ductal carcinoma in situ (DCIS), where cancer cells are only in the glandular tree, is a pre-
malignant condition that may lead to invasive breast cancer. Nowadays, breast cancer is also 
classified into molecular subtypes, namely luminal A and B, HER2-positive and basal. Due to 
logistical and financial reasons, surrogate subtypes are mainly used in clinical practice – 
hormone receptor and HER2 receptor status, and a proliferation measure (usually Ki67). 
Oestrogen-positive (ER+)/HER2-negative breast cancer is the most common subtype, 
comprising about 70% of cases. 
• Breast cancer incidence varies across European countries but overall the lifetime risk is about 
1 in 10 for women. Breast cancer is a substantial health burden on society, and has been 
estimated to cost about 13% of the total cancer healthcare costs in the EU, the highest of any 
cancer, and second in overall economic burden after lung cancer.12 The estimated incidence 
of breast cancer in 2018 in Europe (EU 28 + European Free Trade Association (EFTA) 
countries) was about 416,000 with a European age standardised rate of 145/100,000).13 
Estimated incidence was highest in Belgium (204/100,000), Luxembourg and the Netherlands, 
the lowest in Romania (90/100,000) and Poland; generally, incidence is lower in Southern and 
Eastern Europe, but data from these countries might be incomplete due to issues with cancer 
registries. Estimated mortality in 2018 was about 100,000, with the highest European age 
standardised rates in Croatia (43/100,000), Iceland and Ireland, and the lowest in Spain 
(23/100,000), Finland and Norway.  
 
 
Source: European Cancer Information System. European age standardised rates 
 
Figure 1: European breast cancer mortality and incidence  
 
• There are high survival rates for breast cancer in Europe. The EUROCARE-5 study, the latest 
in the series, reports the 5-year relative survival rate in 2000–2007 at 82%, ranging from 74% 
(Eastern Europe) to 85% (Northern Europe), and survival increased during the study period.14 
Survival was uniformly higher for women in countries with population breast cancer screening. 
The 5-year relative survival was highest in the 45–54 and 55–64 year age groups and 
declined in older patients.  
• Breast cancer mortality rates have declined in the European Union and are predicted to fall 
further, with the largest falls in young women (20-49 years, -22% between 2002 and 2012).15 
The fall in mortality is said to be mainly due to improvements in the management and 
treatment of breast cancer, although early diagnosis and screening are also important. 
Improving breast cancer management in Central and Eastern Europe is a particular priority.15 
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• It is important to note that there has been little progress in extending the median survival of 
patients with advanced or metastatic (stage 4) breast cancer, which remains at about 3 years, 
although longer survival may be seen particularly in the HER2-positive subtype.16,17,18 
 
2.1.2 Risk factors 
• Risk factors for breast cancer in women include older age, family history, previous benign 
breast disease, and a previous breast cancer diagnosis. In addition, several hormonal factors, 
particularly those that expose women to more menstrual cycles, play a role in increasing risk, 
including early menstrual periods, late menopause, less (and later) childbirths and less breast 
feeding.  
• Pathological germline variants in the BRCA1/2 genes can greatly increase risk; other gene 
variants can also add variable risk. Women with dense breasts are more likely to be 
diagnosed with breast cancer. 
• Preventable risk factors include overweight/obesity, lack of physical activity, smoking and 
alcohol consumption. Hormonal replacement therapy increases risk. Women who have had 
radiation therapy to the chest or breast as treatment for other cancers (i.e. lymphoma) are also 
at increased risk. 
• Risk factors for breast cancer in men include older age, family history, BRCA1/2 variants 
(especially in BRCA2), gynecomastia, heavy alcohol intake, liver disease, obesity and 
radiation exposure. 
 
2.1.3 Diagnosis and treatment 
 
Note key ESMO and ESO-ESMO guideline references for diagnosis, treatment and care of early 
breast cancer19 and advanced breast cancer.20 
 
• Breast cancer is one of only three cancers where there is robust evidence for the benefit of 
population screening (cervical and colorectal are the other two) and most European countries 
have introduced mammographic screening programmes, most commonly screening women 
between the ages of 50 and 70 at 2 year intervals to primarily detect small tumours that cause 
no symptoms. However, about an equivalent number of breast cancers are detected by self-
examination for breast lumps and other symptoms including a change in the size or shape of a 
breast, dimpling of skin, inverted nipple, nipple rash and discharge, and a swelling or lump in 
the armpit. Ductal carcinoma in situ (DCIS), which is a non-invasive pre-malignant condition, 
may be asymptomatic or associated with a lump and is detected by mammography (usually 
through the presence of abnormal microcalcifications). 
• Diagnosis should be made by a ‘triple assessment’, comprising clinical assessment (patient 
history and physical examination), mammography and/or ultrasound imaging, and a biopsy (a 
core needle biopsy is necessary; a fine-needle aspiration (FNA) is insufficient and should not 
be performed in the breast, since it has a high rate of false results and does not allow for 
adequate biomarker characterisation). Ultrasound is also used to image the axilla (armpit 
area) for affected lymph nodes, as a common site of spread are ipsilateral axillary nodes, and 
a biopsy/FNA taken if involvement is suspected; if not suspected, to rule out spread to the 
nodes, sentinel lymph node biopsy (SLNB) is a surgical procedure that has become the 
standard of care to identify the first node(s) that could be involved in early breast cancer. 
Breast cancer is commonly staged according to the TNM system and graded for cell 
differentiation (nuclear atypia and proliferation) and tubule formation. All invasive breast 
cancer should be assessed for ER, progesterone (PgR) and HER2 receptor status. The 
distinction between low and high-grade DCIS and invasive cancer is also important. 
• Genetic testing for the BRCA 1/2 mutations is recommended in certain cases as it has 
implications for clinical management.21 
• Early invasive and locally advanced breast cancer are treated with curative intent. Local 
treatments include surgery (breast-conserving surgery (BCS) or mastectomy with sentinel 
lymph node biopsy or axillary dissection) and radiation therapy. Systemic therapy options 
include chemotherapy, endocrine therapy, HER2 targeted therapy and bisphosphonates, 
according to risk of relapse and receptor status, and can be offered before (primary systemic 
therapy, also known as neoadjuvant or preoperative) and/or after surgery (adjuvant therapy). 
• Primary systemic therapy is being used increasingly in higher risk biological subtypes (e.g. 
triple negative and HER2-positive) even in cases where BCS would be possible upfront, since 
this strategy enables personalisation of therapy based on response and facilitates prediction 
of prognosis for individuals based on pathological response. Primary systemic therapy is the 
recommended strategy for locally advanced breast cancer and inflammatory breast cancer. 
For locally advanced disease, surgical treatment varies depending on characteristics at 
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diagnosis and response to therapy, while for inflammatory breast cancer, mastectomy and 
axillary dissection, followed by radiation therapy, is usually necessary even in the presence of 
a good response to primary systemic therapy. 
• Tamoxifen and aromatase inhibitors are approved endocrine agents for ER+ early breast 
cancer. Ovarian ablation (removal of the ovaries) or suppression of oestrogen with drugs may 
also be offered to some premenopausal women with ER+ cancer. 
• BCS followed by breast irradiation (plus endocrine therapy in some cases) is the preferred 
treatment for most DCIS patients, though widespread DCIS may well require treatment by 
mastectomy. Radiotherapy may be avoided in selected cases, i.e. low grade DCIS. 
• Mastectomy or BCS with sentinel lymph node biopsy or axillary dissection and a similar range 
of medical and radiation therapy options are used for male breast cancer. Aromatase 
inhibitors alone should not be used for early breast cancer in male patients.22 
• Systemic therapy with endocrine therapy, chemotherapy and targeted therapy is the strategy 
of choice in advanced/metastatic breast cancer. The choice of systemic therapy depends on 
many factors, including the biology of the tumour, the burden of metastatic disease, 
symptoms, performance status, comorbidities, socioeconomic factors and patient preferences. 
Early and continuous appropriate supportive, palliative and psychosocial support are 
indispensable throughout the management of advanced/metastatic disease. 
• Surgery, radiation therapy and interventional radiology are important to treat certain 
conditions, such as brain or bone metastases, to prevent bone fractures and relieve pain. In 
highly selected de novo (i.e. diagnosed already as stage 4 metastatic cases, locoregional 
therapy of the primary tumour, with surgery and/or radiation therapy, may also be performed. 
 
 
2.2 CHALLENGES IN BREAST CANCER CARE 
 
2.2.1 Screening and detection 
• Mammography screening services are often separate from breast treatment centres, missing 
opportunities for multiprofessional working in assessment and diagnosis. 
• There has been wide publicity given to controversy about the benefits and harms of 
population-based mammography screening, which is one of the flagship health screening 
programmes in many countries. Women must be given information that allows them to make 
informed choices about participation in these programmes. 
• Education on breast health awareness is often lacking in countries and should target girls at 
school as well as adult women.  
• In view of exponential increase in cancer incidence, primary care physicians must be involved 
in many steps of the cancer journey, starting with screening and early diagnosis.23 It is 
essential to promote close collaboration between these specialists and breast centres for a 
fast referral. 
 
2.2.2 Staging and grading 
• There are concerns about the quality of breast cancer pathology services in Europe:  
– They can vary to a considerable extent in the accuracy of assessing parameters 
important for treatment decision-making; few countries are monitoring and assessing 
this variability 
– Most pathology departments are general and may lack pathologists experienced in the 
increasingly complex area of breast pathology and may also lack sufficient volume of 
cases to develop and maintain expertise 
– In many countries there is a shortage of pathologists.  
– Availability of intra-operative pathology assessment is crucial to substantially decrease 
the rate of re-interventions.  
A manifesto by the European Breast Cancer Council addressed these concerns.24 
 
2.2.3 Early breast cancer – treatment and support 
• A wide range of shortcomings and challenges in care result from a lack of multidisciplinary 
breast centres: 
– Overtreatment in all areas (surgery, radiation and medical therapies), often related to 
outdated reimbursement rules 
– Underuse of treatments such as primary systemic therapy 
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– Lack of surgical expertise and experience has led to too many mastectomies, too many 
axillary dissections and too many re-interventions 
– Lack of expertise and experience in breast radiation and medical therapies 
– Lack of oncoplastic/reconstructive expertise. 
• Choosing the right treatment among an increasingly complex range of options has become a 
major challenge for patients and it is important that balanced advice is given by all breast 
specialists.  
• There is a lack of dedicated breast nurses and patient navigators who can help guide 
patients through this complex pare pathway. Breast care nurses are in place in only a few 
European countries at present. Developing breast care nursing is important to offer 
optimised care for patients25,26 and studies have shown that specialist nurses improve patient 
outcomes.27,28 They are essential members of the core MDT. 
• There is a lack of adequate supportive and psychological support. About one third of breast 
cancer patients experience high levels of emotional distress,29,30,31 and about half report 
increased levels of depression and anxiety in the year after diagnosis.32 
• Side-effects from treatments are often not adequately managed.  
• There is a lack of data on treatment of older patients and very young patients. Although 
about 20% of breast cancer occurs in patients 75 years old or older, there is a lack of data 
on management of older patients, especially those who are frail and vulnerable. 
Chronological age alone must not be used to withhold effective therapies.33 
 
2.2.4 Advanced breast cancer (includes inoperable locally advanced and metastatic breast cancer) – 
treatment and support 
• In Europe, most advanced breast cancer patients are still treated outside of MDTs, by 
medical oncologists alone. Treating advanced disease in specialised breast units/centres 
increases access to treatment according to international guidelines, loco-regional 
management of certain types of metastases, correct management of symptoms and side-
effects of therapies, inclusion in clinical trials, and early links to psychosocial supportive and 
palliative care, all of which are associated with higher quality of care and improved 
outcomes. 
• Treatment is complex, can be costly, and often involves multiple lines of therapy with periods 
of good quality of life between treatment spells, with several agents approved in recent 
years. Issues of accessibility to optimal treatment options (e.g. cancer medicines, radiation 
therapy) are crucial and access is highly uneven between countries and within each country 
(see 2.2.7 Inequalities, below). Management of advanced disease in breast centres can 
centralise and optimise access in a cost-effective manner. 
 
2.2.5 Support services and survivorship 
• Many breast cancer patients are of working age or have dependants or children and may 
suffer financial loss as a result of treatment related incapacity. Social support to aid in 
financial and other difficulties may be required but hard to obtain. 
• Services are often also required to help manage secondary effects from treatments that 
affect quality of life, such as physiotherapy and occupational therapy (rehabilitation), 
nutritional counselling and psycho-oncology, but there may be gaps in provision, particularly 
when these services are best delivered in the community in partnership with breast centres.  
• As more patients are being diagnosed at a fertile age, and before they have completed their 
families, fertility preservation is crucial and should be part of the breast centre’s services.  
• Advanced breast cancer patients face a range of survivorship issues such as isolation, lack 
of information and financial hardship. 
 
2.2.6 Genetic testing  
• There are well-established protocols for testing women at high risk of breast cancer, such as 
Ashkenazi Jews or those with many affected family members for variants of the BRCA1/2 
genes, but there is rapidly developing research on lesser risk genes and also in the most 
common genetic variants, SNPs.21,34 The rapid rise in commercial tests and in research on 
genetic breast cancer risk is placing pressure on clinical genetics services and on the 
knowledge base of other health professionals.  
• In particular, there is a major challenge in uncontrolled and sub-standard tests that can raise 
anxiety and raise demand for counselling, and even lead to unnecessary treatment, as set 
out in the 2018 European Breast Cancer Council manifesto.35 
 
2.2.7 Inequalities 
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• Women with higher socioeconomic status in Europe have a higher breast cancer incidence 
but lower mortality than women in lower status groups.36 While higher incidence is linked to 
reproductive factors, hormonal replacement therapy and higher use of opportunistic 
screening, lower fatality seems to be explained by earlier stage of diagnosis, and access to 
optimal treatment. A report from England also shows that socio-economically advantaged 
women are more likely to be diagnosed with breast cancer, and finds that there are 
geographical variations, as women living in disadvantaged areas are more likely to be 
diagnosed at a later stage with a lower chance of survival.37  
• The same report from England also found inequalities related to black and ethnic minority 
status, which are also likely to be seen in other parts of Europe.37 
• There is evidence than many older women (over 70) are not offered the same standard of 
care as younger patients despite being eligible for treatment (see for example the National 
Audit for Breast Cancer in Older Patients (NABCOP) on services in England and Wales – 
(https://www.nabcop.org.uk). They are also more likely to be diagnosed at a later stage. 
• There is also evidence that quality of care for male patients with breast cancer is lower than 
for their female counterparts.38 
• There are substantial inequalities in access to treatment among and within European 
countries. Some Eastern European countries, especially, have shortcomings in radiation 
therapy and drug availability, including inexpensive breast cancer drugs such as tamoxifen 
as well as expensive new therapies, some of which are listed by WHO as essential 
medicines, although lack of access could be due to organisational and not only financial 
constraints. The use of international guidelines (which recommend cost-effective therapies) 
and new tools to objectively evaluate benefit and prioritise effective therapies (such as the 
ESMO Magnitude of Clinical Benefit Scale)39 are potential solutions. The shortage of cancer 
medicines was highlighted in a report from the Economist Intelligence Unit in collaboration 
with ESMO, and needs to be urgently tackled.40 
 
2.2.8 Research 
• Conducting research, in particular clinical research, is associated with better outcomes for 
patients and should be included in the services provided by the breast centre. Currently, 
clinical research in some European countries is oriented towards industry sponsored studies, 
especially those funded by pharmaceutical companies, and academic research must be 
supported by independent sources of funding, as called for by the Clinical Academic Cancer 
Research Forum.41 
• Evidence suggests that clinical research in Europe is not oriented towards investigation of 
antineoplastic drugs effect on endpoints that are most important to patients (i.e. 
improvements in quality of life, reduction of risk of recurrence for the early stages of the 
disease, and life prolongation for advanced disease).42 Therefore, a cornerstone of research 
should be to investigate the impact of intervention on endpoints that are patient oriented. In 
addition, clinical research should provide evidence of interventions’ efficacy and safety from 
real life data, to confirm/question results from clinical trials. 
• Important research topics in breast cancer include:43 
–  Earlier diagnosis, apart from screening 
–  Novel methodology with adaptive trial designs within platforms and validation of novel 
biomarkers of early response 
– Predictive factors and therapy individualisation 
– Escalation and de-escalation of therapy in early breast cancer 
– Identification of treatment strategies that optimise patients’ quality of life without loss of 
quantity. 
• There is an urgent need to increase research in patient groups that are under-represented 
and under-researched in breast cancer studies, particularly older and young women, and 
men. 
• There is a pressing need for the development and incorporation of patient reported 
outcomes/measures (PROs/PROMs), and research on quality of life and survivorship.  
• Patient advocacy groups are valuable partners in all aspects of breast cancer research, from 
epidemiology to treatments to survivorship, and should be involved in all stages of research. 
 
2.2.9 Cancer registration and data availability 
• Cancer registration practice, coverage and quality are highly unequal across Europe.44 
Consequently, basic epidemiological data on incidence, mortality and survival are not 
uniformly available for all countries. Also, only a minority of cancer registries can provide 
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sufficient data for the calculation of parameters necessary for the assessment of outcomes 
and quality of care.45 
• A particular shortcoming in breast cancer is that few cancer registries collect data on 
recurrences, including distant, which means that there are only estimates of the number of 
patients living with incurable disease. This makes it hard for healthcare services and wider 
society to allocate resources for one of the largest populations of advanced cancer patients.    
• There is a need to find ways of improving quality of nationally/internationally collected routine 
data so it can be embedded within clinical trials as outcome data. 
• Cancer registries in Europe should be compatible with each other to analyse data 
collectively. 
• Registries and/or other forms of real-world data should include data on the effects on 
treatment outcomes of the use of OTC (over the counter) medicines or CAM (complementary 
alternative medicines), which are commonly used by cancer patients.46  
• In addition, registries and/or other forms of real-world data should allow for the assessment 
of the true benefit of cancer therapies, evaluating whether results from clinical trials are 
translated into the real-life setting for efficacy and safety. This could also benefit the 
evaluation of efficacy and safety profile of the population unrepresented in randomised 
clinical trials. 
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3. BREAST CENTRE: DEFINITIONS 
 
Breast centre: The place where breast cancer is diagnosed and treated. It has to provide all the 
services necessary, from genetics and prevention, through the treatment of the primary tumour, to 
care of advanced disease, supportive and palliative care, survivorship and psychosocial support. 
 
The breast centre comprises a group of dedicated breast cancer specialists working together as a 
multidisciplinary team (MDT) with access to all the facilities required to deliver high-quality care 
throughout the breast cancer pathway. 
Preferably, all services should be in the same facility, limiting to a minimum the need for the patient to 
travel between locations. Therefore breast centres are encouraged to be organised in one location. 
However, when for organisational reasons this is not possible, some services may be based at 
different locations but must be in the same geographical area, and protocols must be in place for the 
optimal integration of care, guaranteeing multidisciplinary work and timely access, and all sites must 
share the same database for quality assurance and research.  
 
Protocols: Official procedures or systems of rules, including local organisational aspects, for the 
diagnosis and management of breast cancer at all stages, including surveillance and long-term follow-
up.  
 
Breast data audit: Evaluation of quality indicators to identify corrective actions through 
multidisciplinary discussion. 
 
Formal internal review meeting: Evaluation of performance on quality indicators, organisational and 
clinical aspects, audit results, identification and implementation of corrective actions. 
 
Breast multidisciplinary meeting (MDM): Where the core MDT meets to evaluate and plan patient 
care at any step of the diagnostic and treatment process. 
 
Breast clinic: A session at which a number of breast patients are seen for clinical examination and/or 
investigations, counselling, etc. 
 
Breast specialist: A person certified in her/his own discipline and fully trained in management of 
breast cancer. 
 
Breast core MDT members: Breast specialists who are essential for diagnosis and care of breast 
cancer, who spend the majority of their working time in breast cancer and who must participate in 
MDM (except for radiographers, who are part of core team but are not requested to attend the MDM). 
These specialisms are detailed in the essential requirements in section 5: 
 
• Breast radiologist: board-certified specialist in imaging with expertise in breast cancer 
diagnosis (including diagnostic interventional procedures), further assessment and follow-up 
• Breast radiographer: technician specialised in breast imaging examination  
• Breast pathologist: board-certified pathologist with expertise in breast disease 
Breast surgeon: board-certified surgeon with expertise in breast surgery including 
oncoplastic procedures. In some centres this role may be shared by a breast cancer surgeon 
and a reconstructive surgeon working together 
• Breast medical oncologist: board-certified medical oncologist with expertise in breast 
cancer. In some countries (e.g. Germany), systemic therapy for breast cancer patients is 
currently delivered by organ specialists such as gynaecologists, but the goal is that, in the 
near future, systemic therapy is only delivered by medical oncologists. It is crucial that any 
specialist who now delivers systemic therapy has training defined by the ESMO-ASCO Global 
Curriculum for Medical Oncology47 
• Breast radiation oncologist: board-certified radiation oncologist with expertise in breast 
cancer or 
Breast clinical oncologist: in some countries (such as the Nordics and the UK) clinical 
oncologists are professionals who are board-certified in both radiation and medical treatments, 
but must be dedicated to breast cancer   
• Breast care nurse: a nurse with specialist training in breast care nursing  
• Breast data manager: person responsible for breast cancer data management (detailed in 
section 4.10). 
Version 8 November (final) 2019 
 
11 
 
Extended MTD members: Specialists who are consulted during breast cancer care and treatment, 
but are not routinely involved in breast cancer care for every patient. These specialisms are detailed in 
the essential requirements in section 6: 
 
• Psycho-oncologist: professional who identifies distress and psychological morbidity and 
provides psychological interventions to breast cancer patients and their families 
• Geriatric oncologist/geriatrician: geriatrician with cancer expertise who applies geriatric 
assessment for appropriate treatment 
• Oncology pharmacist: pharmacist with expertise in cancer medicines 
• Nuclear medicine physician: board-certified nuclear medicine specialist with expertise in the 
management of breast cancer patients, including sentinel lymph-node technique, molecular 
imaging and theranostics 
• Physiotherapist: professional who provides physical support of patients after breast cancer 
therapies (breast surgery and radiotherapy) 
• Plastic surgeon: board-certified plastic surgeon with expertise in breast reconstruction 
techniques 
• Interventional radiologist: board certified specialist who carries out interventional radiology 
techniques, such as biopsies of metastatic lesions and local management of some types of 
breast cancer metastases such as bone metastases 
• Self-image professional: a specialist in breast or hair prosthesis  
• Palliative care specialist: specialist who provides physical, psychosocial and spiritual care to 
patients who have, or may soon have, severe symptoms and distress from advanced disease 
• Clinical geneticist: medical specialist concerned with the assessment of genetic risk and 
counselling for individuals and families with increased risk of breast cancer 
• Primary prevention professionals: specialists with expertise in physical exercise, diet and 
lifestyle counselling.  
 
All members of the breast centre should have knowledge and skills to provide basic psychological 
care and screen for distress. Qualified care providers other than nurses (e.g. radiation technologists) 
also provide links between patients and the breast team. 
 
To guarantee the availability of other specialists who may be needed for consultations during a breast 
cancer patient’s care pathway, such as nutritionists, fertility preservation experts, cardiologists, 
gynaecologists, neuro-surgeons, orthopaedic surgeons etc., the breast centre must have established 
working arrangements which allow immediate and effective consultation. 
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4. BREAST CENTRE REQUIREMENTS  
 
4.1 Breast centre 
There must be a formal document (that complies with any national regulations) which describes 
organisation of the breast centre and which could include its relationship within the wider cancer 
infrastructure such as the cancer centre and regional cancer network.  
 
4.2 Critical mass 
• A breast centre must be of sufficient size to manage at least 15048,49,50 newly diagnosed cases 
of early breast cancer (all ages, based on surgery) coming under its care each year.6 The breast 
centre must also treat at least 50 cases of metastatic breast cancer a year, independently from 
the line of treatment. 
• The minimum number is necessary to ensure a caseload sufficient to maintain expertise for each 
team member and to ensure cost-effective working of the breast centre.50,51,52 There is good 
quality data that shows that breast cancer survival is related to the number of cases treated per 
annum (see also supporting evidence in Appendix 1, section 1.1.).  
• Minimum caseload for core MDT members: 
o Breast radiologist: 1,000 mammographic exams (5,000 for breast radiologists participating 
in a centralised screening programme), 200 breast ultrasounds and 50 magnetic 
resonance imaging (MRI) studies and 50 breast guided interventions per year  
o Breast radiographer: 1,000 mammograms per year 
o Breast pathologist: 50 preoperative samples and 50 primary breast cancer resections per 
year; should report on 25 metastatic breast surgical specimens (biopsy performed for 
suspicious metastasis) per year 
o Breast surgeon: 50 primary breast surgeries per year 
o Breast medical oncologist: 50 early and 25 metastatic breast cancer patients treated per 
year 
o Breast radiation oncologist: 50 early breast cancer patients treated per year 
o Breast nurse: 50 early and 25 metastatic breast cancer patients cared for per year.  
 
4.3 Screening 
• Where a population-based breast cancer screening programme exists, the breast centre and 
the screening programme should coordinate the assessment of screen-positive cases to 
ensure quality and continuity of care and optimisation of resources. 
• It is recommended that diagnostic assessment of screen-detected imaging findings is done in 
the breast centre. 
• The breast centre should contribute to improving protocols and professional expertise at 
screening centres. 
 
4.4 Patient pathway and protocol 
• The breast centre must develop a patient pathway that ensures continuity of care and describes 
the steps and their timing from diagnosis (or screening) to follow-up including advanced disease, 
palliative care and end of life. This pathway must be backed up by evidence-based protocols 
between care providers which guarantee the continuity of care. 
• The breast centre must identify the guidelines (national and/or international) from which to develop 
the patient pathway and internal protocols must be formally reviewed at least on an annual basis 
at the formal internal review meeting. 
• The patient pathway must be agreed at least by the core MDT members but preferably also by 
extended team members. 
 
4.5 MDT meeting (MDM) 
The breast centre must hold at least weekly a multidisciplinary case management meeting (MDM) to 
discuss diagnostic preoperative and postoperative cases, as well as any other issues related to breast 
cancer patients that requires multidisciplinary discussion. Advanced breast cancer cases must also be 
discussed. 
• At least 95% of all early and locally advanced breast cancer cases and at least 50% of metastatic 
cases must be discussed at the meeting (but in future the goal is that all cases, early and 
metastatic, are discussed at the MDM). At pre-operative stage, the MDM must consider patient-
related factors, tumour-related factors, and treatment options. 
• Team members who must be present: 
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– Discussion of pre-operative breast cancer cases: radiologist, pathologist, medical oncologist, 
surgeon, radiation oncologist, breast nurse and breast data manager 
– Discussion of post-operative cases: pathologist, surgeon, medical oncologist, radiation 
oncologist, breast nurse and breast data manager 
– Discussion of metastatic breast cancer cases: medical oncologist, radiation oncologist, 
breast nurse, radiologist, pathologist, nuclear medicine physician (mandatory if the breast 
centre performs and uses positron emission tomography-computed tomography (PET-CT) 
and recommended if the nuclear medicine service is not inside the hospital), palliative care 
specialist and breast data manager. 
• Other team members must be encouraged to attend and must be available for consultation. 
• Other specialists must be involved if necessary to discuss the clinical situation of patients. 
• Radiological images must be available at the MDM. A photograph of the breast should be 
available to decide the best surgical strategy. Macroscopic pictures or the histology of special 
cases preferably from slides (video microscope or scanned slide) should be shown to support 
understanding of difficult histopathological reports. 
• Evidence on decisions taken for each patient at the meeting must be formally recorded. The name 
of all team members participating in each meeting must be formally recorded. 
• As the patient is usually not present at the MDM and patient preferences must always be taken 
into account, and because the available clinical documents could miss key information, an MDM 
decision might, in some cases, be modified at the time of communication with the patient. For this 
reason, it is important that the breast care nurse present knows the patient’s wishes and 
expectations to ensure they can be shared at the MDM. The clinician who informs and discusses 
with the patient must have the competence to understand why the patient wants a change of the 
recommendation. The reason for change must be documented in the patient chart and the MDM 
must be informed. 
 
4.6 Breast centre coordinator 
The breast centre must have a nominated breast centre coordinator, who can be a healthcare 
professional from any specialty within the core team, responsible for the multidisciplinary approach 
and the full involvement of breast experts from the core disciplines and their regular participation in the 
MDM. The coordinator must ensure there is training and continuing medical education of MDT 
members; ensure the centre has certain breast related research; and ensure the centre’s performance 
is based on high quality data collection and indicators. 
 
4.7 Communication of diagnosis, treatment plan and waiting times 
• A diagnosis must be given to the patient in a face to face meeting as soon as possible and must 
not be given by letter or on the telephone, unless there are exceptional circumstances. A 
preliminary communication on the diagnosis can be given to the patient by each specialist 
according to their competence. 
• The MDT recommendation for the treatment plan should be communicated and discussed with the 
patient by the clinician who has initially seen the patient and/or the clinician who will take primary 
responsibility for providing the first treatment modality. This discussion with the patient is crucial to 
arrive at a shared decision which includes the patient's wishes. 
• Healthcare professionals who deal with cancer patients and their families are recommended to 
have training in and knowledge about communication skills. 
• A breast care nurse must be available to discuss and give any additional information to the patient 
regarding treatment and to give emotional support. A private room should be available. A psycho-
oncologist should also be available to provide more advanced support, when needed, to the 
patient and family. 
• Each patient must be fully informed about each step in the diagnostic and therapeutic pathway 
and must be given adequate time to consider the options and make an informed decision. 
• Patients must be allowed to ask for a second opinion,53 without being penalised in any way. 
• Patients must start primary treatment within a maximum of 4 to 6 weeks from the first diagnostic 
examination in the breast centre54 or first consultation at the breast centre if diagnosed elsewhere. 
• Follow-up should be done within the breast centre according to the local organisation and patient 
preference. 
• The breast centre should offer to plan imaging investigation procedures at the same visit. 
• The breast centre must give advice and support to the patient with symptoms and complaints due 
to hormonal therapy (osteoporosis, gynaecological problems, etc.), referring the patient to the 
appropriate specialist. 
• If the patient does not attend the breast centre for follow-up, the centre should collect follow-up 
information from elsewhere at least yearly for its database. 
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4.8. Patient information 
• Patients must be offered clear verbal and written information (leaflets) that describe the diagnostic 
and treatment options. Leaflets should be personalised for the breast centre in all the main 
languages spoken by the population served. 
• The leaflets should inform patients about diagnostic and treatment options not offered by the 
breast centre if they are covered in current guidelines. 
• The centre should provide information on local support groups and national advocacy 
organisations and the availability of group and/or individual psychological support in the centre. 
• Patients should be provided with a copy of their rights as outlined in the breast cancer resolution 
of the European Parliament.7 
 
4.9 Advocacy group/patient volunteer group 
 
It is recommended that the breast centre collaborates with a local/national advocacy group or patient 
volunteer group. This group should collaborate with the centre to offer activities and projects dedicated 
to breast centre patients. 
 
4.10 Quality control 
• The breast centre must have a database to collect data on all primary and advanced breast 
cancer patients it treats. 
• Data collection is essential to monitor compliance with national and/or international quality 
indicators, standards and guidelines, and it is also a basis for scientific research at the breast 
centre. 
• The breast centre must achieve the minimum standard for EUSOMA’s mandatory quality 
indicators (as described in EUSOMA’s quality indicators in breast cancer care, 2017, and future 
updates).54 If a minimum standard is not achieved the breast centre must put in place corrective 
actions and re-evaluate measures at an agreed date.  
• Data must include source of referral, clinical and pathological diagnosis, treatment, follow-up and 
clinical outcomes. 
• The breast centre must also collect in the database, or in a separate register, data on all surgical 
operations performed on benign disease (with the exclusion of inflammatory disease, operations 
for cosmetic reasons or prophylactic surgery). 
• The breast centre must have a data manager who works in the core team under the supervision of 
a medical doctor designated by the clinical coordinator. The data manager is responsible for data 
collection and analysis and for the organisation of audit meetings. Data should preferably be 
collected during the patient management process. The data manager must inform the breast 
centre team about performance quality according to indicators and about any emerging criticality. 
• The breast centre should participate in external benchmarking activities (comparison of results 
with those of other centres). 
• Breast centres should yearly monitor their outcomes at least on the following items: local 
recurrence rate, distant recurrence rate, sequelae (surgical, radiation and systemic therapy) 
aesthetic outcomes, functional outcomes. 
• Breast centres are strongly advised to collect and analyse validated patient reported outcomes 
(PROs) using validated measurements (patient reported outcome measures, PROMs). 
• The centre must have a formal internal review meeting at least once a year to discuss all 
performance aspects, i.e. audit results, continuity of care, organisational and clinical aspects, 
critical issues, results of corrective actions, new projects, etc. Core team members must 
participate in this meeting, and extended members should participate. Minutes of the meeting and 
the list of participants must be kept.  
 
4.11 Education 
The breast centre should provide teaching on a local, national or international basis. Some breast 
centres may have expertise in teaching certain subjects, such as reconstruction, screening, 
pathology/molecular biology, systemic therapies, radiation oncology, etc. The breast centre should 
organise at least one teaching course per year at local, regional, national or international level. 
 
4.12 Research 
Research is an essential part of training specialists and underpins every aspect of clinical practice, 
and breast centres should be involved in both clinical (i.e. clinical trials) and translational research. 
The breast centre should record the numbers of patients participating in clinical trials and collect 
details of any other research activities, such as evaluation of newly introduced techniques. The breast 
centre should aim to include at least of 5% of patients in clinical trials each year.  
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Figure 2: Breast cancer centre schematic  
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5. CORE MDT MEMBERS 
 
All core MDT members should comply with EUSOMA’s guidelines on standards for training specialised 
health professionals who deal with breast cancer.55 All specialists must work according to protocols 
and national/international guidelines. All specialists working in the core team must comply with all 
specialist related requirements indicated in the sections below. 
 
5.1 Breast radiology 
 
Breast radiologists 
• The breast centre must have at least 2 dedicated breast radiologists. 
• To be considered a breast specialist, a radiologist must spend at least 50% of their working time 
on breast imaging. 
• Breast radiologists must be involved in the full assessment of breast patients, including invasive 
procedures (core biopsy, ultrasound guided, stereotactic vacuum assisted biopsy, etc.). 
• Breast radiologists should participate in national or regional radiology quality assurance schemes. 
• Where possible, radiologists involved in the assessment of breast patients should participate in 
both breast screening and symptomatic breast imaging. 
• Breast radiologists must read a minimum of 1,000 mammography cases per year and conduct 
and read a minimum of 200 breast ultrasound studies (targeted, diagnostic or screening) per year, 
and a minimum of 50 breast MRI studies per year. 
• Breast radiologists participating in a centralised screening programme must have a workload of at 
least 5,000 cases per year.10 
• Breast radiologists must attend at least one diagnostic clinic per week for symptomatic patients or 
further assessment of breast screening recall. 
• Each breast radiologist must perform a minimum of 50 breast guided interventions per year. 
• Double reading of mammograms is encouraged both for screening and symptomatic 
mammography when the breast centre workload is less than 3,000 per year; double reading of 
breast MRI studies is encouraged when the MRI workload is less than 200 per year. 
• All imaging studies taken outside the centre must be reviewed by breast centre radiologists. 
 
Examinations 
• The breast radiology team must perform: 
◊ Clinical examination 
◊ Mammography 
◊ Ultrasound and Doppler ultrasound of the breast and axilla 
◊ Breast MRI 
◊ Core biopsy – free-hand, ultrasound guided, mammography guided 
◊ Vacuum-assisted biopsy under mammographic or breast MRI guidance. If this is not available 
within the breast centre, there must be a formal agreement with a local diagnostic service 
◊ Lesion localisation and bracketing under ultrasound, mammography, and MRI guidance. If 
this is not available within the breast centre, there must be a formal agreement with a local 
diagnostic service 
◊ Multidisciplinary working should allow all standard investigations for triple assessment (clinical 
examination, mammography and/or ultrasound and biopsy) to be completed in one visit (but 
respecting patient’s preferences) and maximum within 5 working days 
• Non-surgical diagnosis by needle biopsy of both benign and malignant disease is the required 
standard. 
• Palpable lesions must be examined via ultrasound and where there is an ultrasound correlate, 
needle biopsy must be done under ultrasound guidance. 
• Needle biopsy must be image-guided for all non-palpable lesions. 
• Image-guided biopsy of non-palpable lesions must be done under the guidance of an appropriate 
imaging method; usually, the same imaging method that was used to establish the diagnosis 
should be used to guide biopsy. 
• MRI-guided and mammography guided biopsy can be replaced by ultrasound guided biopsy; 
however, in these cases, the radiologist must ensure that the target identified on ultrasound 
corresponds to the target seen on the other imaging method. 
• Primary diagnosis using open surgical biopsy is not recommended and only acceptable in 
exceptional cases. 
• Core or vacuum assisted biopsy is the preferred technique for sampling the breast. 
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• Core biopsy is also considered the preferred technique for sampling axillary lymph nodes. Fine 
needle aspiration cytology (FNAC) may also be used but requires the availability of a pathologist 
who is experienced in interpreting cytology of FNAC specimens. 
• The breast centre must use a single formal imaging risk classification (e.g. BI-RADS or the 
European classification). 
• The breast centre must collaborate with board certified imaging experts who carry out 
interventional radiology techniques, such as biopsy of metastatic lesions in breast cancer patients.  
 
Imaging equipment 
The breast centre must have: 
• Digital mammography 
• Stereotactic biopsy attachment and/or dedicated prone biopsy table 
• Methods for mammography guided stereotactic lesion localisation and bracketing (wire or clip) 
• Ultrasound equipped with a small parts probe ≥ 12 MHz and including Doppler function 
• Methods for ultrasound guided core biopsy 
• Methods for ultrasound guided lesion localisation and bracketing procedures 
• Breast MRI with ≥ 1.5T, dedicated bilateral breast coil; dedicated equipment for breast 
immobilisation is strongly encouraged 
• Access to MRI-guided vacuum-assisted biopsy and MRI-guided lesion localisation or bracketing, 
either in-house or by formal agreement with an affiliated diagnostic service 
• Digital storage of all images (mammograms, ultrasound documentation, MRI studies) 
• Equipment no older than 10 years, unless carefully maintained and complying with national and/or 
international standards 
• Routine quality control of all equipment used for breast imaging, according to national protocols 
and/or European guidelines.10 If the centre follows a national protocol, this must include essential 
points such as assessment of image quality of the monitors and estimate of the maximum 
average of glandular dose. 
 
Breast radiographers 
• Radiographers must have training in breast diagnosis to perform mammography. 
• The breast centre must have at least 2 breast radiographers, each performing at least 1,000 
mammograms a year. 
• Radiographers should also attend refresher courses at least every 3 years. 
• The breast centre must have protocols on the periodical review of the technical performance of 
radiographers.  
• Radiographers should participate in regular audit of their technical performance. 
• Breast centres must have protocols on quality control on a daily basis and must follow guidelines 
on equipment quality control as detailed in European guidelines.  
 
5.2 Breast pathology 
 
Breast pathologists 
• The breast centre must have at least 2 dedicated breast pathologists (1 of whom should be 
nominated as the breast pathology lead for the MDT). A pathologist at the breast centre must 
spend at least 50% of their working time on breast disease. 
• A breast centre pathologist must report on at least 50 early breast cancer resections per year and 
should report on at least 100 pre-operative samples (with a mandatory minimum of 50) and 25 
metastatic breast surgical specimens per year. 
• Breast pathologists must take part in regional, national and/or European breast cancer quality 
assurance schemes. 
• Breast pathologists must be familiar with their national and/or European quality standards and 
guidelines. 
 
Procedures 
• Breast pathology reports must include histological type (according to the WHO Classification of 
Tumours of the Breast), grading (according to WHO and EU guidelines: Elston and Ellis modified 
Bloom-Richardson grading system), immunohistochemistry (IHC) for diagnosis and for oestrogen, 
progesterone and HER2 receptors status. In situ hybridisation (ISH) analyses of HER2 must be 
obtained from reference laboratories. Reports should also include evaluation of proliferation. 
• Ki67 is the preferred marker to assess proliferation56 but is not mandatory. Caution is needed 
about the reproducibility of IHC for Ki67. If used, the St Gallen International Breast Cancer 
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Conference has suggested calibrating a common scoring method to achieve high inter-laboratory 
reproducibility in Ki67 on centrally stained tissue microarray slides.56  
• For reporting core biopsies, breast pathologists must use the B1-5 classification as described in 
European guidelines.10 Reporting by 2 pathologists of core biopsies is encouraged. 
When the patient is treated in an institution different from that performing the pathological 
diagnosis, the tumour blocks and slides must be requested for revision by the breast pathologist. 
• Breast tissue samples must be kept as long as possible because the patient can relapse more 
than 20 years after the first diagnosis. At least 1-2 FFPE blocks most representative of the lesion 
must be stored in perfect conditions (controlled temperature, humidity and parasites) and kept for 
at least 20 years or according to the national law, whichever is longer.57 An archive of digital slides 
should be considered. 
 
Equipment 
• The pathology laboratory must be equipped with microscopes, cryocut, histoprocessors, 
microtome staining machines and immunostainers, and a system for obtaining surgical sample 
and/or slide pictures. 
• The equipment must be replaced every 10 years unless carefully maintained and complying with 
national and/or international standards. 
 
5.3 Breast surgery 
 
Breast surgeons 
• The breast centre must have at least 2 dedicated breast surgeons with training in breast surgery. 
• Breast surgeons must spend at least 50% of their working time on breast disease. 
• Any breast surgeon at the breast centre must carry out primary surgery as first operator on at least 
50 newly diagnosed breast cancers a year. If the centre has surgeons in training, those 
responsible for supervising trainees might perform fewer than 50 primary cases as first operator. 
In this case documentation on their role as second operator supervising trainees must be 
available. 
• Breast surgeons must be able to perform sentinel lymph node biopsy in all settings (adjuvant, 
neoadjuvant, recurrence), all types of mastectomy (nipple sparing, skin sparing, simple) and 
guided surgery for non-palpable tumours, and breast conserving surgery. 
• Breast surgeons must be able to perform risk-reducing techniques for high-risk patients. 
• Breast surgeons should advise and where necessary treat women with benign disease, e.g. cysts, 
fibroadenoma, mastalgia, inflammatory conditions. 
• The breast surgical team should be able to offer level I and II oncoplastic techniques; breast 
surgeons should have additional training in oncoplastic procedures to offer the patient surgical 
options. 
 
 
5.4 Breast medical oncology 
 
Breast medical oncologists 
• The breast centre must have at least 2 breast medical oncologists dedicated to breast cancer. Any 
breast medical oncologist at the breast centre must spend 50% of their working time on breast 
cancer. 
• Breast medical oncologists must treat a minimum of 50 early and 25 metastatic breast cancer 
patients per year. 
• Breast medical oncologists must supervise systemic therapy and all decision-making processes 
for its use. 
• Follow-up information on all patients treated with systemic therapy must be collected, even if 
patients are treated outside the breast centre. 
 
 
5.5 Breast radiation oncology 
 
Breast radiation oncologists 
• The breast centre must have at least 2 radiation oncologists dedicated to breast cancer. Any 
breast radiation oncologist at the breast centre must spend at least 50% of their working time on 
breast cancer. 
• Breast radiation oncologists must treat a minimum of 50 early breast cancer patients per year. 
They must also have experience with palliative treatments.  
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• Breast radiation oncologists must be competent to determine the need for techniques such as 
intensity modulated radiotherapy (IMRT), image guided radiotherapy (IGRT), cardiac-sparing 
radiotherapy, brachytherapy, stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery.  
• Radiation oncologists must be adequately trained in breast cancer contouring, including regional 
nodes, and use international guidelines such as those developed by the fEuropean Society for 
Radiotherapy and Oncology (ESTRO). 
• Radiation oncology units must develop and work to an evidence-based breast radiation therapy 
clinical protocol that is reviewed and updated regularly: this should include dose objectives and 
constraints for each breast radiation technique. 
• It is recommended that all radiation oncology units have a dedicated breast radiation planning and 
treatment MDT with radiation oncologists, radiotherapy physicists, dosimetrists and therapy 
radiographers to review and manage challenging cases including those who cannot be treated 
within the standard clinical protocols. 
• If the radiation oncology unit is not available within the hospital, the breast centre must have an 
agreement with a radiation oncology unit and breast radiation oncologists must attend the MDM at 
the breast centre. In all situations, breast radiation oncologists must have full access to all patient 
data regarding diagnosis and treatment and must be involved in the patient management plan. 
• Follow-up information on all patients treated with radiation therapy must be collected, even if 
patients are treated and/or followed-up outside the breast centre. 
 
Breast radiation technicians 
• It is strongly recommended that the breast centre has dedicated radiotherapy physicists, 
dosimetrists and therapy radiographers. At least 1 medical physicist and 2 radiation 
therapists/dosimetrists should have breast cancer as a main interest. 
 
Equipment and techniques 
 
• The staffing and technical platform should fulfil the requirements described by the EORTC 
Radiation Oncology Group.58 Therefore, the minimum equipment in a radiation oncology unit must 
include at least 2 megavoltage units, a CT scanner dedicated to treatment preparation, and a 3D 
treatment planning system. Treatment machines must be equipped with IGRT tools to verify 
accurateness of treatment delivery. Equipment must be no older than 12 years, unless carefully 
maintained, upgraded and complying with national and/or international standards. 
• Radiation therapy planning must be carried out according to optimised (3D) procedures based on 
anatomically defined volumes, with treatments individualised to 3D target volume definitions and 
contouring. Field-based treatments must be abandoned.  
• The evaluation must be done using tools such as dose volume histograms, taking into account 
predefined objectives for the dose distribution for the target volumes and dose constraints for 
organs at risk (including as a minimum the heart and lungs). Respiratory control should be 
available and used according to predefined indications including patient risk factors and doses to 
heart and lungs. 
• Experience is essential especially in techniques aimed at optimising the homogeneity of dose 
distribution, including IMRT and IGRT, partial breast irradiation, and cardiac sparing techniques 
such as breath-hold.  
• Access to 3D brachytherapy is highly recommended.  
• SBRT and radiosurgery must be available for treatment of oligometastases and brain metastases. 
• The breast centre must have a quality assurance programme for the entire radiation oncology 
process, including for the machines/infrastructure. If specific equipment or working procedures are 
in place for treating breast cancer patients, they must be included in the quality assurance 
programme. Sufficient ongoing education for all healthcare professionals is essential. 
• Clinical and translational radiation therapy research is encouraged. 
 
 
5.6 Breast cancer nursing 
 
Breast care nurses 
• The breast centre must have at least 2 breast care nurses dedicating all their working time to 
breast cancer. 
• Breast care nurses must see a minimum of 50 early and 25 metastatic breast cancer patients per 
year. 
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• Breast care nurses must be available: 
◊ Throughout the patient pathway from diagnosis through treatment and follow-up, to offer 
practical advice, emotional support, explanation of the treatment plan and information on 
side-effects27 
◊ At the time of communication of recurrent or metastatic disease 
◊ At follow-up clinics. 
• Breast care nurses must also: 
◊ Help to develop protocols, patient pathways, information and implementation of nursing 
research27 
◊ Document their meetings with patients. Record keeping is an essential part of nursing 
care59 and promotes high quality, effective and safe care60 as the information can be 
important for use by other professionals in the MDT.61 
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6. EXTENDED MDT AND OTHER SERVICES 
 
 
6.1 Psychological support/psycho-oncology 
 
• Basic psychological counselling and emotional support must be provided by a breast nurse or 
another professional trained in the psychological aspects of breast cancer care. If psychological 
morbidity cannot be dealt with effectively by them, patients must be referred to a psycho-
oncologist or psychiatrist. 
• Distress must be recognised, monitored, documented and treated promptly at all stages of 
disease. It must be assessed in all patients using a tool such as a distress thermometer.62 
• A psycho-oncologist must be available throughout the disease continuum to patients and their 
families at the breast centre to help patients deal with common psychological issues in breast 
cancer such as fear of recurrence, body image disruption, sexual dysfunction, treatment-related 
anxieties, intrusive thoughts about illness, marital /partner communication, feelings of vulnerability, 
existential concerns regarding mortality, fertility, work-related issues, depression, and, in particular 
for advanced breast cancer patients, fear of dying, coping with an incurable disease and 
continuous treatment, and feelings of isolation and guilt. 
• A psychiatrist must also be available to patients. 
 
 
6.2 Geriatric oncology 
 
• The breast centre must have access to geriatricians with oncology experience. 
• The role of the geriatric oncologist is to coordinate recommendations to other specialists about the 
need for personalised interventions for older patients with increased vulnerability to stressors. 
• All older patients (70+) and patients who appear frail or have severe comorbidity must be 
screened with a quick, simplified frailty screening tool, such as the adapted Geriatric-8 (G8) 
screening tool.63,64  
• Frail patients as suggested by the screening tool should undergo a full geriatric assessment.65 The 
assessment can be based on self-report combined with objective assessments that can be 
performed by the breast nurse in collaboration with a physician (geriatrician/internist/medical 
oncologist). 
• Cognitive impairment affects all aspects of treatment – ability to consent, compliance with 
treatment, and risk of delirium – and screening using tools such as Mini-Cog66 is advised. A 
geriatrician, geriatric psychiatrist or neurologist should preferably be involved with impaired 
patients. 
• For frail patients, the geriatrician should be present in the MDT meeting, or easily available for 
consultation, to discuss treatment options aligned with the patient’s goals for care. 
 
 
6.3 Oncology pharmacy 
 
• Oncology pharmacists must have experience with antineoplastic treatments and supportive care; 
interactions between drugs; drug dose adjustments based on age, liver and kidney function, and 
toxicity profile; utilisation and monitoring of pharmacotherapy; patient counselling and 
pharmacovigilance; and knowledge of complementary and alternative medicines. 
• Oncology pharmacists must liaise with medical oncologists to discuss cancer treatments, including 
interactions with other treatments. 
• Oncology pharmacists must be involved in the clinical trials research of the breast centre. 
• Oncology pharmacists must use the European QuapoS guidelines (European Society of Oncology 
Pharmacy).67 Oncology drugs must be prepared in the pharmacy and dispensing must take place 
under the supervision of the oncology pharmacist. 
 
 
6.4 Nuclear medicine 
 
• The breast centre must have access to nuclear medicine specialists for procedures relevant to 
breast cancer care.  
• Sentinel node biopsy (SNB) is included in the standard of care and must be available. The nuclear 
medicine physician should oversee the procedure and identify the nodes in planar and single 
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photon emission computerised tomography (SPECT) or SPECT/CT images (recommended if 
available), as well as marking the location on the skin, and may collaborate with the surgeon 
during surgery in locating the lesion with an intraoperative probe.  
• The nuclear medicine physician must oversee all aspects of PET/CT for patients who require this 
procedure either with 18F-FDG or with other radiotracers, including indications, multidisciplinary 
algorithms and management protocols.68,69,70,71,72 
• There is evidence of the efficacy of 18F-FDG-PET/CT in selected clinical indications in breast 
cancer, such as staging of high-risk patients, treatment planning, response monitoring, and 
detection of recurrent disease69,70,71,71 18F-FDG-PET/CT should not be used for surveillance for 
recurrent disease in asymptomatic patients.  
• Conventional nuclear medicine such as bone scan and cardiac multigated acquisition (MUGA) 
should also be available. 
• Equipment should preferably be onsite, be less than 10 years old, unless carefully maintained and 
complying with national and/or international standards, ready for radiation treatment planning, and 
have an integrated picture archiving and communication system/radiology information system 
(PACS/RIS) and updated workstations. 
• The nuclear medicine department must be able to perform daily verification of protocols and to 
react accordingly. Quality-assurance protocols must be in place. An option for ensuring the high 
quality of PET/CT scanners is provided by the European Association of Nuclear Medicine (EANM) 
through EARL accreditation. 
 
6.5 Physiotherapy 
 
• There must be at least 2 physiotherapists with expertise in lymphatic drainage for the treatment of 
lymphoedema and its related sequelae, and to ensure good shoulder mobility. 
• Physiotherapists with expertise in rehabilitation of metastatic patients with sequelae of bone or 
brain metastases and their treatments must be available for breast centre patients. 
• A rehabilitation programme for cancer patients who require assistance in the recovery of functional 
status after treatment must be available. 
• Physiotherapists must collaborate with the palliative care service and with medical oncologists and 
breast nurses at the breast centre. 
 
6.6 Breast plastic surgery 
 
The role of breast plastic surgeons depends on the organisation of the breast centre. In most centres, 
microsurgery reconstruction techniques are performed by breast plastic surgeons as part of the breast 
surgical team. If necessary the breast centre must make arrangements with 1 or 2 breast plastic 
surgeons with a special interest in breast reconstructive and reshaping techniques. 
 
6.7 Interventional radiology 
 
The breast centre must have access to interventional radiologist expertise. Bone metastases carry an 
important risk of developing skeleton-related events that impact quality of life. Besides surgery and 
radiotherapy, percutaneous image-guided cementoplasties/closed internal fixation/thermal ablation 
have a growing role in the treatment of these metastases. 
 
6.8 Self-image support 
 
• There must be a breast prosthesis fitting service within the breast centre or referral to a service 
outside the centre. 
• There must be counselling about hair prosthesis and referral to recommended services. 
 
 
6.9 Palliative care  
Palliative care, as defined by the World Health Organization, applies not only at end of life but 
throughout cancer care. Palliative care means patient and family-centred care that enhances quality of 
life by preventing and treating physical, psychosocial and spiritual suffering early in the course of 
advanced disease73,74,75 
Palliative care services include general palliative care provided by the oncology professionals at the 
breast centre who are responsible for breast cancer care and specialised palliative care provided by a 
Version 8 November (final) 2019 
 
23 
 
multidisciplinary palliative care team.76,77,78 Close collaboration between the breast centre and 
palliative care teams is crucial. 
 
• There must be a specialist palliative care team that provides expert outpatient and inpatient care 
including specialist physicians and nurses, working with social workers, chaplains, 
physiotherapists, occupational therapists, dieticians, pain specialists and psycho-oncologists. In 
practice: 
◊ The breast centre team, in particular medical oncologists and breast nurses, is usually 
responsible for basic palliative care such as symptom control and screening for disease and 
treatment related symptoms and suffering 
◊ Patients with severe symptom burden or unmet physical, psychosocial or spiritual needs must 
be referred to a specialist palliative care team, irrespective of the cancer-specific treatment 
plan.79 
• The most common physical, psychosocial and spiritual symptoms/problems and functional 
impairments must be assessed in all patients using tools such as the Edmonton Symptom 
Assessment Scale (ESAS)80 or EORTC questionnaire on quality of life in palliative cancer care 
patients (QOL-C15-PAL – https://qol.eortc.org/questionnaire/qlq-c15-pal). 
• The palliative care team must have good knowledge of cancer disease and cancer treatments 
including adverse effects of treatment and rehabilitation needs to be able to offer holistic care in 
collaboration with other professionals. Early palliative care should be provided in conjunction with 
cancer specific treatments for treatment-related distressing symptoms such as pain and 
dyspnoea, and for psychosocial and spiritual care. 
• The palliative care team must support family members and carers, and have experience of taking 
care of younger patients and their families. 
• Palliative care specialists and oncologists must aspire to meet the standard of ESMO Designated 
Centres of Integrated Oncology and Palliative Care (http://www.esmo.org/Patients/Designated-
Centres-of-Integrated-Oncology-and-Palliative-Care). 
• To ensure continuity of care at home, the palliative care team must work with primary or 
community care providers or be able to provide direct care at home, and must provide end-of-life 
care. 
 
 
6.10 Clinical genetics 
 
• The breast centre must have a dedicated clinical geneticist responsible for a genetics clinic, or 
an agreement with a hospital where this service is available. 
• The clinical genetics service must offer: 
◊ Diagnostic surveillance with protocols for high-risk women including screening MRI 
according to the level of risk 
◊ Risk assessment counselling and testing for BRCA mutations in high-risk groups in 
accordance with national and/or international protocols 
◊ Genetic testing for BCRA mutations; a molecular geneticist must be accessible for 
consultation 
◊ Protocols for risk reduction surgeries and chemoprevention 
◊ Psychological support to facilitate an accurate perception of risk and its acceptance, 
to assure adherence to surveillance plans, and to support the patient with complex 
decision-making 
◊ Registration of patient data in an appropriate database and involvement in research 
◊ BRCA mutation testing for metastatic breast cancer patients, in view of the potential 
clinical implications. At present, no other genes are recommended for testing in the 
metastatic setting, including with any next generation sequencing (NGS) test.20  
 
 
6.11 Prevention  
A growing body of evidence documents the effectiveness of physical activity and a correct diet for a 
variety of outcomes in breast cancer survivors. There is evidence from randomised trials that physical 
activity in breast cancer patients has positive effects on physical functions, psychological outcomes 
and quality of life.81,82 There is evidence from well conducted observational studies and meta-
analyses83,84 that physical activity reduces overall and cause specific mortality in breast cancer 
patients.85,86,87 There is preliminary evidence that physical activity produces beneficial effects on 
biomarkers linked to better prognosis and on local recurrence.88,89,90 A World Cancer Research Fund  
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report recommends that breast cancer survivors follow the same physical exercise and diet 
recommendations as for the general population.91 
 
• Breast centres must offer or recommend physical activity and dietary intervention programmes to 
their patients; compliance with such programmes should be assessed and encouraged during 
regular follow-up visits. 
• Lifestyle counselling should include home-based exercise92 and is an important supportive role for 
the breast care nurse.93  
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APPENDIX 1: SUPPORTING EVIDENCE AND INFORMATION 
 
1.1 CRITICAL MASS/VOLUME REQUIREMENTS/MDT WORKING 
• The concept of the multidisciplinary breast centre – which may also treat other breast conditions 
as well as cancer – is now well established in several countries in Europe and North America. 
There are some national specifications that may complement the one set out in this paper.  
• The evidence base is partly built on procedures by specialist breast surgeons. For example, in 
1996 a study comparing survival outcomes by specialist and non-specialist breast cancer 
surgeons in Scotland showed that the absolute 5 year survival rate was 9% higher and the 10 year 
survival 8% higher for patients cared for by specialist surgeons, with a relative reduction in risk of 
dying of 16%.94 A later paper from the United States, in 2003, found a similar absolute benefit, of 
7% at 5 years, and a relative risk reduction of 33%, of treatment by specialist surgical 
oncologists.95  
• Hospital and surgical volume have also been confirmed as positive factors. A systematic review of 
the volume-outcome relationship with breast cancer surgery found that improved survival was 
significantly associated with high volume providers.96 Another study found that higher surgeon and 
hospital volume significantly predicted lower subsequent re-operation after breast conserving 
surgery and after adjustment for socio-demographic and clinical variables.97 A recent study from 
the United States reported that treatment at high volume centres is associated with improved 
survival for breast cancer patients regardless of stage, and that high case volume could serve as a 
proxy for the institutional infrastructure required to deliver complex multidisciplinary breast cancer 
treatment.98  
• Looking at multidisciplinary aspects, an observational cohort study evaluated the effects on breast 
cancer survival on nearly 14,000 women in Scotland, and found MDT working was associated with 
a 18% lower breast cancer mortality at 5 years.99 By comparing an area where MDT working was 
introduced with areas that had not implemented it, the authors found that it probably improves 
patient outcomes by influencing various aspects of care, such as adherence to guidelines, nurse 
education, increased surgical volume and experience, and improved interdisciplinary working. A 
study in Taiwan that compared those receiving MDT treatment with those without found that MDT 
intervention significantly increased the breast cancer survival rate.100 A population study from a 
region in Germany suggested there may be evidence of increased mortality if breast cancer 
patients do not receive guideline compatible treatment.101 
• There are studies that report changes in treatment plans following MDT discussion. In single 
institution studies in the United States and Canada, a second evaluation of patients referred to a 
multidisciplinary tumour board led to changes in the recommendations for surgical management in 
77 of 149 of patients studied (52%),102 and management plans changed in 41% of cases 
presented, the majority due to new/clarified diagnostic information.103  A UK study found that MDT 
meetings enable cross-speciality interrogation of requests for prophylactic mastectomy, minimise 
unnecessary surgery and restrict mastectomy to those likely to derive maximum benefit.104 
• A global survey, completed by principal investigators from 39 countries participating in a phase III 
trial, showed that mandatory MDT working for breast cancer ranged from about two-thirds of 
centres in Eastern/Western Europe to only a quarter in South America and a third in Asia.105 But a 
review of breast cancer MDT working notes about this survey that most centres that reported 
having mandatory MDT care lacked national or regional guidelines regarding composition or 
practice of MDT work to ensure consistency of provision (only 19% reported having such 
guidelines).106 
• Among the most compelling recent evidence is a study on Germany’s breast cancer services. It 
reports that low-volume hospitals with ≤30 cases/year had a statistically significant 3-fold 
increased risk of death after breast conserving treatment and a significantly increased the 
likelihood of postoperative complications after both breast conserving treatment and breast 
ablative therapy.107 Also noted was that length of stay was shorter and non-routine discharge was 
lower at high-volume hospitals and that the likelihood of receiving beast conserving surgery was 
significantly higher at high-volume hospitals. Another study in Germany found that adherence to 
breast cancer surgery quality processes is higher in hospitals that treat more cases.108   
 
1.2 PATHWAYS  
• Care for all cancer patients should be organised in pathways that cover the patient’s journey, and 
pathways must correspond to current national and European evidence-based clinical practice 
guidelines on diagnosis, treatment and follow-up. The European Pathway Association defines a 
care pathway as “a complex intervention for the mutual decision making and organisation of care 
processes for a well-defined group of patients during a well-defined period”. This broad definition 
covers terms such as clinical, critical, integrated and patient pathways that are also often used 
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See http://e-p-a.org/care-pathways and also the WHO framework on integrated people-centred 
health services, http://www.who.int/servicedeliverysafety/areas/people-centred-care. 
• There are many examples of care pathways for breast cancer given the pioneering role this 
cancer has played in developing multidisciplinary care. Examples are from the National Institute 
for Health and Care Excellence (NICE) in the UK109,110 and Cancer Council Australia.111 A paper 
from the UK also gives a good example and emphasises the role that care pathways play with the 
MDT as the integral part of the system.112 The UK was one of the first countries to establish the 
value of MDTs for a cancer type, and together with defined care pathways has been instrumental 
in addressing variations in outcomes among breast units and regions in the country. A key point 
reiterated is that the management of breast cancer patients is a complex undertaking, requiring 
coordination among specialist team members to enable high-quality individualised care. 
 
1.3 PATIENT ADVOCACY 
Patient advocacy for breast cancer is the most widely available and well organised of any cancer type 
in the world. The principal European-wide organisation is Europa Donna, which counts more than 50 
national member organisations or representatives in Europe (https://www.europadonna.org). Europa 
Donna has been instrumental in lobbying at European level for the adoption of declarations and 
resolutions on universal screening and multidisciplinary breast cancer services in the European Union. 
Many European countries have dedicated advocacy groups, such as Breast Cancer Care 
(https://www.breastcancercare.org.uk) and Breast Cancer Now (http://breastcancernow.org) in the UK, 
Brustkrebs in Germany (http://brustkrebsdeutschland.de), and the Dutch Breast Cancer Association 
(https://borstkanker.nl).  
There is a need to develop more advocacy and support for advanced/metastatic breast cancer 
patients. This can be achieved by dedicated advocacy groups, such as in the US with MetaVivor and 
the Metastatic Breast Cancer Network, or through the development of dedicated resources within 
advocacy groups. Examples of the latter are the recently launched MBC advocacy programme and 
website of Europa Donna (https://mbc.europadonna.org) and the MBC programmes of Komen 
(http://www.komen.org) and Breast Cancer Network Australia (http://www.bcna.org.au). The recently 
created ABC Global Alliance is a multistakeholder platform, coordinated by ESO (European School of 
Oncology), and is dedicated to advanced/metastatic breast cancer patients globally 
(http://www.abcglobalalliance.org). 
 
 
1.4 ACCREDITATION/CERTIFICATION, AUDIT AND QUALITY 
There is wide evidence of the benefit of external audits (i.e. certification or accreditation) for improved 
performance and outcomes in many fields, including medicine in general and oncology in particular.  
There are a variety of methods for organisational quality assessment, which can differ with respect to 
several characteristics, e.g. voluntary versus compulsory, and collegial (driven by professionals) 
versus regulatory (driven by governments). Another important difference is between assessment of 
organisational and quality systems aspects and those that focus on clinical aspects or specialty 
services.113  
All breast centres must consider a voluntary certification process at national and/or European level. 
Such schemes include the following.  
 
• A voluntary certification scheme (accredited by Accredia) based on the EUSOMA requirements 
has been developed and accredited (http://www.breastcentrescertification.com). It evaluates the 
patient pathway in terms of services, health professionals, equipment, organisation, and data 
collection. A yearly report is issued to monitor compliance with EUSOMA’s quality indicators. 
• The German Cancer Society certification system for cancer centres in Germany was launched in 
2003, initially for breast cancer (https://www.krebsgesellschaft.de/gcs/german-cancer-
society/certification.html). It is a voluntary initiative that has been subject to evaluation in several 
papers and now covers breast cancer centres in Austria, Switzerland and northern Italy, as well as 
Germany. The German Cancer Society’s report for the audit year 2017 details the performance of 
certified breast cancer centres. It covered 275 clinical sites and includes provision of psycho-
oncology and social services counselling.114 
• The National Accreditation Program for Breast Centers (NAPBC) is a programme run by the 
American college of Surgeons and made its first award in 2008 (https://www.facs.org/quality-
programs/napbc). It accepts applications from centres outside of the US.   
• Organisation of European Cancer Institutes (OECI) accreditation is a European accreditation and 
quality improvement programme for cancer centres and comprehensive cancer centres which 
evaluates the whole quality system in cancer including research, and which can help to integrate 
breast centres within the wider cancer centre infrastructure (https://www.oeci.eu).115 The 
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programme was launched in 2008 and the quality standards and indicators are accredited by the 
International Society for Quality in Healthcare (ISQua). 
 
European Commission Initiative on Breast Cancer 
The European Commission Initiative on Breast Cancer (ECIBC, http://ecibc.jrc.ec.europa.eu) 
comprises two working groups. The Guideline Development Group is developing a new edition of the 
European guidelines for quality assurance in breast cancer screening and diagnosis, and the Quality 
Assurance Scheme Development Group (QASDG) is developing a set of voluntary quality and safety 
requirements for breast cancer services in Europe. 
QASDG has defined the care pathway for breast cancer screening and care, the interventions and 
services to be considered, the quality domains to be included and how the scheme can be 
implemented in Europe. Importantly, QASDG is taking a modular approach to adapt to different breast 
service configurations in Europe. Outputs, expected in 2020, will be a quality assurance manual, a 
self-assessment tool and a quality indicators calculator. 
 
Other national and international quality examples and projects 
 
• NICE in the UK updated its quality standard for breast cancer services in 2016;116 it comprises 
6 statements, and NICE considered that others previously listed are no longer priorities for 
improvement (such as on ultrasound evaluation of the axilla, oncoplastic breast conserving 
surgery, those with early invasive cancer are offered the same care regardless of age). As 
such the current quality standard is a guide to issues that may also be identified in other 
countries as priorities. They are:  
◊ People with suspected breast cancer referred to specialist services are offered the triple 
diagnostic assessment in a single hospital visit 
◊ People with biopsy proven invasive breast cancer or ductal carcinoma in situ (DCIS) are 
not offered a preoperative MRI scan unless there are specific clinical indications for its 
use 
◊ People with ER+, HER2- and lymph node-negative early breast cancer who are at 
intermediate risk of distant recurrence are offered gene expression profiling with 
Oncotype DX 
◊ People with newly diagnosed invasive breast cancer and those with recurrent breast 
cancer (if clinically appropriate) have ER and HER2 status of the tumour assessed 
◊ People with breast cancer who develop metastatic disease have their treatment and 
care managed by an MDT 
◊ People with locally advanced, metastatic or distant recurrent breast cancer are assigned 
a key worker. 
 
• The National Clinical Audit Programme in the UK published the first National Audit for Breast 
Cancer in Older Patients (NABCOP) in 2017, on services in England and Wales 
(https://www.nabcop.org.uk). The need for the audit was based on concern that delivery of 
care by NHS services in the UK has found breast cancer services have a non-standard and 
variable approach to the management of older patients. The report says that breast cancer 
units should review patient and carer involvement with decision making, develop protocols to 
assess the health of older patients, identify patients who could benefit from specialist older 
person teams, and define the contributions of specialists such as nurses and palliative care 
doctors for care of older people, among other recommendations. 
 
• In the Netherlands, the NABON Breast Cancer Audit (NBCA) started collecting data from all 
Dutch hospitals from 2011 with the aims of nationwide evaluation of quality parameters, 
evaluation of guideline adherence, and weekly feedback to participating institutions. After 4 
years of auditing, patients being discussed in pre- and post-operative multidisciplinary team 
meetings improved (2011: 83% and 91%; 2014: 98% and 99%, respectively).117 Tumour 
margin positivity rates after breast-conserving surgery for invasive cancer requiring re-
operation were consistently low, but other indicators, for example, the use of an MRI scan 
prior to surgery or immediate breast reconstruction following mastectomy showed 
considerable hospital variation. 
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• The mission of the Breast Centres Network is to promote synergy among breast units by 
connecting specialists and personnel working in the field, and to help breast cancer patients 
find the right place for care or for a second opinion (http://www.breastcentresnetwork.org). It is 
run by the European School of Oncology and currently lists more than 220 breast units 
globally. 
 
 
1.5. EDUCATION AND TRAINING  
 
It is essential that each breast cancer centre provides professional clinical and scientific education on 
the disease and that at least one person is responsible for this programme. Healthcare professionals 
working in breast cancer must also receive training in psychosocial oncology, palliative care, 
rehabilitation and communication skills. Such training must also be incorporated into specialist 
postgraduate and undergraduate curriculums for physicians, nurses and other professionals. An 
expert group at the European Commission has endorsed a recommendation for multidisciplinary 
training of cancer specialists to improve the value of MDTs and patient care.118  
 
Breast cancer training varies greatly among European countries and there is a need for 
multidisciplinary initiatives such as the Certificate of Competence in Breast Cancer from the European 
School of Oncology, which started in 2017.119 There is a great variability in breast cancer surgery 
training in Europe and it is imperative to develop quality standards for breast cancer surgery training to 
ensure that patients receive standardised and certified surgical management regardless of the country 
in which they are treated.120 A curriculum for breast care nurses has been introduced by the European 
Oncology Nursing Society (EONS).27  
 
1.6 CLINICAL RESEARCH AND REGISTRIES 
• Centres treating breast cancer should have clinical research programmes (either their own 
research or as a participant in programmes led by other centres/cooperative groups). The 
research portfolio should have both interventional and non-interventional projects and include 
academic research. The MDT must assess all new patients for eligibility to take part in academic 
and industry sponsored clinical trials at the centre or in research networks. 
• Collaboration within national and/or international European academic research networks or 
cooperative groups is strongly recommended since high-quality clinical and translational research 
can no longer be performed in isolated centres. Breast cancer research is well organised 
worldwide, with most countries having at least one national breast cancer group and with BIG 
(Breast International Group, http://www.bigagainstbreastcancer.org), which is an umbrella 
organisation of national and international breast cancer cooperative groups. BIG has longstanding 
collaboration with North American breast cancer groups for large global projects. 
• In countries where clinical trials are less available, centres treating breast cancer should engage 
with policymakers to investigate referring patients to other countries (as proposed with European 
Reference Networks) and should be prepared to participate in clinical trials from an organisational 
standpoint. Researchers at other centres should be considered as part of the extended MDT for at 
least annual discussion of clinical trial participation. Generally, pan-European action should be 
taken to increase participation of breast cancer patients in clinical trials (both industry-sponsored 
and academic), and internet access to local clinical trial databases should be developed. 
• Older adults are currently underrepresented in cancer clinical trials despite having a 
disproportionate burden of disease. Strategies to increase the participation of older adults must be 
implemented and trials designed to take their needs into account. 
• Other underrepresented breast cancer patients in clinical trials are male breast cancer patients 
and young premenopausal women. Strategies to increase their participation must be 
implemented. 
• Correlative biomarker research is a crucial part of all phases of clinical studies and requires close 
cooperation with between basic and clinical research groups, as well as the availability of high-
quality certified biobanks, at local, national or international level. 
• Cancer control plans must include high-quality population and clinical cancer registries for breast 
cancer to inform both research and improve quality of care. A population example is Nordcan 
(http://www-dep.iarc.fr/NORDCAN), which includes breast cancer in 50 cancer types in the Nordic 
countries; and for screening, CANSCREEN5 (http://canscreen5.iarc.fr). Important bodies are the 
International Association of Cancer Registries (IACR) and the European Network of Cancer 
Registries (ENCR), and the European Commission’s Joint Research Centre (JRC), which with 
ENCR is working on harmonisation of data and registration processes.  
Version 8 November (final) 2019 
 
29 
 
 
 
 
 
 
 
 
  
Version 8 November (final) 2019 
 
30 
 
REFERENCES  
                                                 
1
 Højgaard, L., Löwenberg, B., Selby, P., Lawler, M., Banks, I., Law, K., et al., 2017. The European Cancer Patient’s Bill of 
Rights, update and implementation 2016. ESMO Open 1 (6), e000127. https://doi.org/10.1136/esmoopen-2016-000127. 
2
 Albreht, T., Kiasuma, R., Van den Bulcke, M., 2017. Cancon Guide – Improving cancer control coordination. 
https://cancercontrol.eu/archived/cancercontrol.eu/guide-landing-page/index.html. 
3
 Prades, J., Remue, E., van Hoof, E., Borras, J.M., 2015. Is it worth re-organising cancer services on the basis of 
multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient 
outcomes. Health Policy 119 (4), 464–474. http://dx.doi.org/10.1016/j.healthpol.2014.09.006. 
4
 Cardoso, F., Cataliotti, L., Costa, A., Knox, S., Marotti, L., Rutgers, E., et al., 2017. European Breast Cancer Conference 
manifesto on breast centres/units. Eur. J. Cancer 72, 244–250. http://dx.doi.org/10.1016/j.ejca.2016.10.023. 
5
 EUSOMA, 2000. The requirements of a specialist breast unit. Eur. J. Cancer 36, 2288–2293. https://doi.org/10.1016/s0959-
8049(00)00180-5. 
6
 Cataliotti, L., Costa, A., Daly, P.A., Fallowfield, L., Freilich, G., Holmberg, L., et al., 1999. Florence statement on breast cancer: 
forging the way ahead for more research on and better care in breast cancer. Eur. J. Cancer 35 (1), 14–15. 
https://doi.org/10.1016/S0959-8049(98)00384-0. 
7
 European Parliament, 2006. Resolution on breast cancer in the enlarged European Union. 18 October 
2006. http://bit.ly/1XT0WTu. 
8
 European Parliament, 2015. Written declaration submitted under rule 136 of the rules of procedure on the fight against breast 
cancer in the European Union. 27 April 2015. http://bit.ly/1zS6aHB. 
9
 Wilson, A.R.M., Marotti, L., Bianchi, S., Biganzoli, L., Claassen, S., Decker, T. et al., 2013. The requirements of a specialist 
breast centre. Eur. J. Cancer. 49, 3579–3587. https://doi.org/10.1016/j.ejca.2013.07.017. 
10
 European Commission, 2006. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth 
Edition. https://bit.ly/31YwoY0. 
11
 Lakhani, S.R., Ellis. I.O., Schnitt, S.J., Tan, P.H., van de Vijver, M.J., 2012. WHO Classification of Tumours of the Breast. 
Fourth Edition. WHO Classification of Tumours, Volume 4. https://bit.ly/2NmFXvL. 
12
 Luengo-Fernandez, R., Leal, J., Gray, A., Sullivan, R., 2013. Economic burden of cancer across the European Union: a 
population-based cost analysis. Lancet Oncol. 14 (12), 1165–1174. https://doi.org/10.1016/S1470-2045(13)70442-X. 
13
 European Commission. ECIS – European Cancer Information System. https://ecis.jrc.ec.europa.eu. 
14
 Sant, M., Chirlaque Lopez, M.D., Agresti, R., Sánchez Pérez, M.J., Holleczek, B., Bielska-Lasota, M., 2015. Survival of 
women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study. Eur. J. Cancer 51 
(15), 2191–2205. https://doi.org/10.1016/j.ejca.2015.07.022. 
15
 Carioli, G., Malvezzi, M., Rodriguez, T., Bertuccio, P., Negri, E., La Vecchia, C., 2017. Trends and predictions to 2020 
in breast cancer mortality in Europe. Breast 36, 89–95. https://doi.org/10.1016/j.breast.2017.06.003. 
16
 Cardoso, F., Spence, D., Mertz, S., Corneliussen-James, D., Sabelko, K., Gralow, J., 2018. Global analysis of 
advanced/metastatic breast cancer: Decade report (2005-2015). Breast 39, 131–138. 
https://doi.org/10.1016/j.breast.2018.03.002. 
17
 Fietz, T., Tesch, H., Rauh, J., Boller, E., Kruggel, L., Jänicke, M., et al., 2017. Palliative systemic therapy and overall survival 
of 1,395 patients with advanced breast cancer - Results from the prospective German TMK cohort study. Breast 34, 122–130. 
https://doi.org/10.1016/j.breast.2017.05.014. 
18
 Gobbini, E., Ezzalfani, M., Dieras, V., Bachelot, T., Brain, E., Debled, M., et al., 2018. Time trends of overall survival among 
metastatic breast cancer patients in the real-life ESME cohort. Eur. J. Cancer 96, 17–24. 
https://doi.org/10.1016/j.ejca.2018.03.015. 
19
 Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I.T., et al., 2019. Early breast cancer: ESMO 
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30 (8), 1194–1220. 
https://doi.org/10.1093/annonc/mdz173.  
20
 Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., 2018. 4th ESO-ESMO International Consensus 
Guidelines for Advanced Breast Cancer (ABC 4). Ann. Oncol. 29 (8), 1634–1657. https://doi.org/10.1093/annonc/mdy192. 
21
 Paluch-Shimon, S., Cardoso, F., Sessa, C., Balmana, J., Cardoso, M.J., Gilbert, F., et al., 2016. Prevention and screening in 
BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines 
for cancer prevention and screening. Ann. Oncol. 27 (suppl 5), v103–v110. https://doi.org/10.1093/annonc/mdw327. 
22
 Korde, L.A., Zujewski, J.A., Kamin, L., Giordano, S., Domchek, S., Anderson, W.F., et al., 2010. Multidisciplinary meeting on 
male breast cancer: summary and research recommendations. J. Clin. Oncol. 28 (12), 2114–2122. 
https://doi.org/10.1200/JCO.2009.25.5729. 
23
 Banks, I., Weller, D., Ungan, M., Selby, P., Aapro, M., Beishon. M., et al, 2019. ECCO Essential Requirements for Quality 
Cancer Care: Primary care. Crit. Rev. Oncol. Hematol. 142, 187–199. https://doi.org/10.1016/j.critrevonc.2019.07.007.  
 
24
 Tot, T., Viale, G., Rutgers, E., Bergsten-Nordström, E., Costa, A., 2015. Optimal breast cancer pathology manifesto. Eur. J. 
Cancer 51, 2285–2288. https://doi.org/10.1016/j.ejca.2015.06.127. 
 
Version 8 November (final) 2019 
 
31 
 
                                                                                                                                                        
25
 European Oncology Nursing Society (EONS), 2013. Cancer Nursing Curriculum 2013. 4th Edition. 
https://www.cancernurse.eu/documents/EONSCancerNursingCurriculum2013.pdf.  
26
 Voigt, B., Grimm, A., Lossack, M., Klose, P., Schneider, A., Richter-Ehrenstein, C., 2011. The breast care nurse: the care 
specialist in breast centres. Int. Nurs. Rev. 58 (4), 450–453. https://doi.org/10.1111/j.1466-7657.2011.00893.x. 
27
 Eicher, M., Kadmon, I., Claassen, S., Marquard, S., Pennery, E., Wengstrom, Y., et al., 2012. Training breast 
care nurses throughout Europe: the EONS postbasic curriculum for breast cancer nursing. Eur. J. Cancer 48 (9), 1257–1262. 
https://doi.org/10.1016/j.ejca.2011.07.011. 
28
 Luck, L., Chok, H.N., Scott, N., Wilkes, L., 2017. The role of the breast care nurse in patient and family care. J. Clin. Nurs. 26 
(21–22), 3422–3429. https://doi.org/10.1111/jocn.13704. 
29
 Zabora, J., BrintzenhofeSzoc, K., Curbow, B., Hooker, C., Piantadosi, S., 2001. The prevalence of psychological distress by 
cancer site. Psychooncology 10 (1), 19–28. https://doi.org/10.1002/1099-1611(200101/02)10:1%3C19::AID-
PON501%3E3.0.CO;2-6. 
30
 Okamura, M., Yamawaki, S., Akechi, T., Taniguchi, K., Uchitomi, Y., 2005. Psychiatric disorders following first breast cancer 
recurrence: prevalence, associated factors and relationship to quality of life. Jpn. J. Clin. Oncol. 35(6):302-9. 
https://doi.org/10.1093/jjco/hyi097. 
31
 Hegel, M.T., Moore, C.P., Collins, E.D., Kearing, S., Gillock, K.L., Riggs, R.L., 2006. Distress, psychiatric syndromes, and 
impairment of function in women with newly diagnosed breast cancer. Cancer 107 (12), 2924–2931. 
https://doi.org/10.1002/cncr.22335. 
32
 Burgess, C., Cornelius, V., Love, S., Graham, J., Richards, M., Ramirez, A., 2005. Depression and anxiety in women with 
early breast cancer: five year observational cohort study. BMJ 330 (7493), 702. https://doi.org/10.1136/bmj.38343.670868.D3. 
33
 Biganzoli, L., Wildiers, H., Oakman, C., Marotti, L., Loibl, S., Kunkler, I., et al., 2012. Management of elderly patients with 
breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of 
Breast Cancer Specialists (EUSOMA). Lancet Oncol. 13 (4), e148–160. https://doi.org/10.1016/S1470-2045(11)70383-7. 
34
  National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk 
Assessment: Breast and Ovarian. https://www.nccn.org/professionals/physician_gls.  
35
 Rutgers, E., Balmana, J., Beishon, M., Benn, K., Evans, D.G., Mansel, R., et al. 2019.  European Breast Cancer Council 
manifesto 2018: Genetic risk prediction testing in breast cancer. Eur. J. Cancer 106, 45–53. 
https://doi.org/10.1016/j.ejca.2018.09.019. 
36
 Lundqvist, A., Andersson, E., Ahlberg, I., Nilbert, M., Gerdtham, U., 2016. Socioeconomic inequalities in breast cancer 
incidence and mortality in Europe – a systematic review and meta-analysis. Eur. J. Public Health 26 (5), 804–813. 
https://doi.org/10.1093/eurpub/ckw070. 
37
 All-Party Parliamentary Group on Breast Cancer, 2018. A mixed picture: An inquiry into geographical inequalities in breast 
cancer. https://bit.ly/2CfF8ON.  
38
 Cardoso, F., Bartlett, J.M.S., Slaets, L., van Deurzen, C.H.M., van Leeuwen-Stok, E., Porter, P., et al., 2018. 
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG 
International Male Breast Cancer Program. Ann. Oncol. 29 (2), 405–417. https://doi.org/10.1093/annonc/mdx651. 
39
 Cherny, N.I., Dafni, U., Bogaerts, J., Latino, N.J., Pentheroudakis, G., Douillard, J.Y., et al, 2017. ESMO-Magnitude of Clinical 
Benefit Scale version 1.1. Ann. Oncol. 28 (10), 2340–2366. https://doi.org/10.1093/annonc/mdx310. 
40
 Economist Intelligence Unit (EIU), ESMO, 2017. Cancer medicines shortages in Europe: Policy recommendations to prevent 
and manage shortages. https://bit.ly/32dsnPm. 
41
 Negrouk, A., Lacombe, D., Cardoso, F., Morin, F., Carrasco, E., Maurel, J., et al, 2017. Safeguarding the future of 
independent, academic clinical cancer research in Europe for the benefit of patients. ESMO Open 2 (3), e000187. 
https://doi.org/10.1136/esmoopen-2017-000187. 
42
 Davis, C., Naci, H., Gurpinar, E., Poplavska, E., Pinto, A., Aggarwal, A., 2017. Availability of evidence of benefits on 
overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug 
approvals 2009-13. BMJ 359, j4530. https://doi.org/10.1136/bmj.j4530. 
43
 Cardoso, F., Harbeck, N., Barrios, C.H., Bergh, J., Cortés, J., El Saghir, N., 2017.  Research needs in breast cancer. Ann. 
Oncol. 28 (2), 208–217. https://doi.org/10.1093/annonc/mdw571. 
44
 Forsea, A.M., 2016. Cancer registries in Europe – going forward is the only option. Ecancermedicalscience 10, 641, 
https://doi.org/10.3332/ecancer.2016.641. 
45
 Siesling, S., Louwman, W.J., Kwast, A., van den Hurk, C., O’Callaghan. M., Rosso, S., et al., 2015. Uses of cancer registries 
for public health and clinical research in Europe: Results of the European Network of Cancer Registries survey among 161 
population-based cancer registries during 2010-2012. Eur. J. Cancer 51 (9), 1039–1049. 
https://doi.org/10.1016/j.ejca.2014.07.016. 
 
Version 8 November (final) 2019 
 
32 
 
                                                                                                                                                        
46
 Johnson, S.B., Park, H.S., Gross, C.P., Yu, J.B., 2018. Complementary medicine, refusal of conventional cancer therapy, 
and survival among patients with curable cancers. JAMA Oncol. 4 (10), 1375–1381. 
https://doi.org/10.1001/jamaoncol.2018.2487. 
47
 Dittrich, C., Kosty, M., Jezdic, S., Pyle, D., Berardi, R., Bergh, J., et al., 2016. ESMO / ASCO Recommendations for a Global 
Curriculum in Medical Oncology Edition 2016. ESMO Open 1 (5), e000097. https://doi.org/10.1136/esmoopen-2016-000097. 
48
 Odofin, O., Harris, K., Paramanathan, N., Laws, S., Rainsbury, R., 2011. The impact of providing an oncoplastic service on 
the workload of a specialist breast unit. Breast J. 17 (4), 371–376. https://doi.org/10.1111/j.1524-4741.2011.01097.x. 
49
 Roohan, P.J., Bickell, N.A., Baptiste, M.S., Therriault, G.D., Ferrara, E.P., Siu, A.L., 1998. Hospital volume 
differences and five-year survival from breast cancer. Am. J. Public Health 88 (3), 454–457. 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1508346. 
50
 Vrijens, F., Stordeur, S., Beirens, K., Devriese, S., Van Eycken, E., Vlayen, J., 2012. Effect of hospital volume on processes 
of care and 5-year survival after breast cancer: a population-based study on 25000 women. Breast 21 (3), 261–266. 
https://doi.org/10.1016/j.breast.2011.12.002. 
51
 Grilli, R., Minozzi, S., Tinazzi, A., Labianca, R., Sheldon, T.A., Liberati, A., 1998. Do specialists do it better? The impact of 
specialization on the processes and outcomes of care for cancer patients. Ann. Oncol. 9 (4), 365–374. 
https://www.ncbi.nlm.nih.gov/pubmed/9636826. 
52
 Hoffmann J., 2006. Analysis of surgical and diagnostic quality at a specialist breast unit. Breast 15 (4), 490–
497. https://doi.org/10.1016/j.breast.2005.11.001. 
53
 Clauson, J., Hsieh, Y.C., Acharya, S., Rademaker, A.W., Morrow, M., 2002. Results of the Lynn Sage Second-Opinion 
Program for local therapy in patients with breast carcinoma. Changes in management and determinants of where care is 
delivered. Cancer 94 (4), 889–894. https://doi.org/10.1002/cncr.10318. 
54
 Biganzoli, L., Marotti, L., Hart, C.D., Cataliotti, L., Cutuli, B., Kühn, T., et al., 2017. Quality indicators in breast cancer care: an 
update from the EUSOMA working group. Eur. J. Cancer 86, 59–81. https://doi.org/10.1016/j.ejca.2017.08.017. 
55
 Cataliotti, L., De Wolf, C., Holland, R., Marotti, L., Perry, N., Redmond, K., et al., 2007. Guidelines on the standards for the 
training of specialised health professionals dealing with breast cancer. Eur. J. Cancer 43 (4), 660–675. 
https://doi.org/10.1016/j.ejca.2006.12.008. 
56
 Curigliano, G., Burstein, H.J., Winer, E., Gnant, M., Dubsky, P., Loibl, S., et al. De-escalating and escalating treatments for 
early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast 
Cancer 2017. Ann. Oncol. 28 (8), 1700–1712. https://doi.org/10.1093/annonc/mdx308. 
57
 Ministry of Health, Italy, 2016. Tracking, collection, transport, preservation and storage of cells and tissues for diagnostic 
investigations of pathological anatomy. https://bit.ly/34pjnIu. 
58
 Budiharto, T., Musat, E., Poortmans, P., Hurkmans, C., Monti, A., Bar-Deroma, R., et al., 2008. Profile of European 
radiotherapy departments contributing to the EORTC Radiation Oncology Group (ROG) in the 21st century. Radiother. Oncol. 
88 (3), 403–410. https://doi.org/10.1016/j.radonc.2008.05.013. 
 
59
 Prideaux, A., 2011. Issues in nursing documentation and record-keeping practice. Br. J. Nurs. 20 (22), 1450–1454. 
https://doi.org/10.12968/bjon.2011.20.22.1450. 
60
 Mykkänen, M., Miettinen, M., Saranto, K., 2016. Standardized nursing documentation supports evidence-based nursing 
management. Stud. Health Technol. Inform. 225, 466–470. http://ebooks.iospress.nl/publication/43089. 
61
 Saranto K., Kinnunen, U.M., 2009. Evaluating nursing documentation – research designs and methods: systematic review. J. 
Adv. Nurs. 65 (3), 464-476. https://doi.org/10.1111/j.1365-2648.2008.04914.x. 
62
 National Comprehensive Cancer Network. NCCN Guidelines: Distress 
Management.https://www.nccn.org/professionals/physician_gls/default.aspx. 
63
 Petit-Monéger, A., Rainfray, M., Soubeyran, P., Bellera, C.A., Mathoulin-Pélissier, S., 2016. Detection of frailty in elderly 
cancer patients: Improvement of the G8 screening test. J. Geriatr. Oncol. 7 (2), 99–107. 
https://doi.org/10.1016/j.jgo.2016.01.004. 
64
 Clegg A., Rogers L., Young, J., 2015. Diagnostic test accuracy of simple instruments for identifying frailty in community-
dwelling older people: a systematic review. Age Ageing 44 (1), 148–152. https://doi.org/10.1093/ageing/afu157. 
65
 Wildiers, H., Heeren, P., Puts, M., Topinkova, E., Janssen-Heijnen, M.L., Extermann, M., et al., 2014. International Society of 
Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J. Clin. Oncol. 32 (24), 2595–2603. 
https://doi.org/10.1200/JCO.2013.54.8347. 
66
 Borson, S., Scanlan, J.M., Chen, P., Ganguli, M., 2003. The Mini-Cog as a screen for dementia: validation in a population-
based sample. J. Am. Geriatr. Soc. 51 (10), 1451–1454. http://dx.doi.org/10.1046/j.1532-5415.2003.51465.x. 
67
 European Society of Oncology Pharmacy, 2018. Quality Standard for the Oncology Pharmacy Service (QuapoS 6). 
http://www.esop.li/activities.php. 
68
 Boellaard, R., Delgado-Bolton, R., Oyen, W.J., Giammarile, F., Tatsch, K., Eschner, W., et al., 2015. FDG PET/CT: EANM 
procedure guidelines for tumour imaging: version 2.0. Eur. J. Nucl. Med. Mol. Imaging 42 (2), 328–
354. https://doi.org/10.1007/s00259-014-2961-x. 
 
 
Version 8 November (final) 2019 
 
33 
 
                                                                                                                                                        
69
 Jadvar, H., Colletti, P.M., Delgado-Bolton, R., Esposito, G., Krause, B.J., Iagaru, A.H., et al., 2017. 
Appropriate use criteria for 18F-FDG PET/CT in restaging and treatment response assessment of malignant disease. J. Nucl. 
Med. 58 (12), 2026–2037. https://doi.org/10.2967/jnumed.117.197988. 
 
70
 Caresia Aroztegui, A.P., García Vicente, A.M., Alvarez Ruiz, S., Delgado Bolton, R.C., Orcajo Rincon, J., Garcia Garzon. J.R., 
et al., 2017. 18F-FDG PET/CT in breast cancer: evidence-based recommendations in initial staging. Tumour Biol. 39 (10), 
1010428317728285. https://doi.org/10.1177/1010428317728285. 
 
71
 Pennant, M., Takwoingi, Y., Pennant, L., Davenport, C., Fry-Smith, A., Eisinga, A., et al., 2010. A systematic review of 
positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for 
the diagnosis of breast cancer recurrence. Health Technol. Assess. 14 (50), 1–103. https://doi.org/10.3310/hta14500. 
72
 Cheng, X., Li, Y., Liu, B., Xu, Z., Bao, L., Wang, J., 2012. 18F-FDG PET/CT and PET for evaluation of pathological response 
to neoadjuvant chemotherapy in breast cancer: a meta-analysis. Acta Radiol. 53 (6), 615–627. 
https://doi.org/10.1258/ar.2012.110603. 
 
73
 Haun, M.W., Estel, S., Rücker, G., Friederich, H.C., Villalobos, M., Thomas, M., et al., 2017. Early palliative 
care for adults with advanced cancer. Cochrane Database Syst. Rev. 6, CD011129. 
https://doi.org/10.1002/14651858.CD011129.pub2.  
74
 Gaertner, J., Siemens, W., Meerpohl, J.J., Antes, G., Meffert, C., Xander, C., et al., 2017. Effect of specialist palliative 
care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic 
review and meta-analysis. BMJ 357, j2925. https://doi.org/10.1136/bmj.j2925.  
75
 Kavalieratos, D., Corbelli, J., Zhang, D., Dionne-Odom, J.N., Ernecoff, N.C., Hanmer, J., et al., 2016. 
Association between palliative care and patient and caregiver outcomes: a systematic review and meta-analysis. JAMA 316 
(20), 2104–2114. https://doi.org/10.1001/jama.2016.16840. 
76
 Jordan, K., Aapro, M., Kaasa, S., Ripamonti, C.I., Scotté, F., Strasser, F., et al., 2018. European Society for Medical Oncology 
(ESMO) position paper on supportive and palliative care. Ann. Oncol. 29 (1), 36–43. https://doi.org/10.1093/annonc/mdx757. 
77
 Ferrell, B.R., Temel, J.S., Temin, S., Alesi, E.R., Balboni, T.A., Basch, E.M., et al., 2017. Integration of palliative care into 
standard oncology care: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin. Oncol. 35 (1), 96–
112. https://doi.org/10.1200/JCO.2016.70.1474. 
78
 Quill, T.E., Abernethy, A.P., 2013. Generalist plus specialist palliative care – creating a more sustainable model. N Engl. J. 
Med. 368 (13), 1173–1175. https://doi.org/10.1056/NEJMp1215620.  
79
 Hui, D., Mori, M., Watanabe, S.M., Caraceni, A., Strasser, F., Saarto, T., et al., 2016. Referral criteria for outpatient specialty 
palliative cancer care: an international consensus. Lancet Oncol. 17 (12), e552–e559. https://doi.org/10.1016/S1470-
2045(16)30577-0. 
80
 Hui, D., Bruera, E., 2017. The Edmonton Symptom Assessment System 25 years later: past, present, and future 
developments J. Pain Symptom Manage. 53 (3), 630–643. https://doi.org/10.1016/j.jpainsymman.2016.10.370. 
81
 Fong, D.Y., Ho, J.W., Hui, B.P., Lee, A.M., Macfarlane, D.J., Leung, S.S., et al. 2012. Physical activity for cancer 
survivors: meta-analysis of randomised controlled trials. BMJ 344, e70. https://doi.org/10.1136/bmj.e70. 
82
 Cramp, F., Byron-Daniel, J., 2012. Exercise for the management of cancer related fatigue in adults. Cochrane Database Syst. 
Rev. 11, CD006145. https://doi.org/10.1002/14651858.CD006145.pub3. 
83
 Fontein, D.B., de Glas, N.A., Duijm, M., Bastiaannet, E., Portielje, J.E., Van de Velde, C.J., et al., 2013. Age and the effect of 
physical activity on breast cancer survival: A systematic review. Cancer Treat. Rev. 39 (8), 958–965. 
https://doi.org/10.1016/j.ctrv.2013.03.008. 
84
 Ballard-Barbash, R., Friedenreich, C.M., Courneya, K.S., Siddiqi, S.M., McTiernan, A., Alfano, C.M., 2012. Physical 
activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J. Natl. Cancer Inst. 104 (11), 815–840. 
https://doi.org/10.1093/jnci/djs207. 
85
 Bradshaw, P.T, Ibrahim, J.G., Khankari, N., Cleveland, R.J., Abrahamson, P.E., Stevens, J., et al., 2014. Post-diagnosis 
physical activity and survival after breast cancer diagnosis: the Long Island Breast Cancer Study. Breast Cancer Res. 
Treat. 145 (3), 735–742. https://doi.org/10.1007/s10549-014-2966-y. 
86
 Hamer, J., Warner, E., 2017. Lifestyle modifications for patients with breast cancer to improve prognosis and optimize overall 
health. CMAJ 189 (7), E268–E274. https://doi.org/10.1503/cmaj.160464. 
87
 Dieli-Conwright, C.M., Lee, K., Kiwata, J.L., 2016. Reducing the risk of breast cancer recurrence: an evaluation of 
the effects and mechanisms of diet and exercise. Curr. Breast Cancer Rep. 8 (3), 139–150. https://doi.org/10.1007/s12609-016-
0218-3. 
88
 Ibrahim, E.M., Al-Homaidh, A., 2011. Physical activity and survival after breast cancer diagnosis: meta-analysis of published 
studies. Med. Oncol. 28 (3), 753–765. https://doi.org/10.1007/s12032-010-9536-x. 
89
 Schmid, D., Leitzmann, M.F., 2014 Association between physical activity and mortality among breast cancer and 
colorectal cancer survivors: a systematic review and meta-analysis. Ann. Oncol. 25 (7), 1293–1311. 
https://doi.org/10.1093/annonc/mdu012. 
90
 Löf, M., Bergström, K., Weiderpass, E., 2012. Physical activity and biomarkers in breast cancer survivors: a systematic 
review. Maturitas 73 (2), 134–142. https://doi.org/10.1016/j.maturitas.2012.07.002. 
 
Version 8 November (final) 2019 
 
34 
 
                                                                                                                                                        
91
 World Cancer Research Fund, 2014. Diet, Nutrition and Physical Activity and Breast Cancer Survivors. Revised 2018. 
www.wcrf.org/sites/default/files/Breast-Cancer-Survivors-2014-Report.pdf. 
92
 Hardcastle, S.J., Cohen, P.A., 2017. Effective physical activity promotion to survivors of cancer is likely to be home based and 
to require oncologist participation. J. Clin. Oncol. 35 (32), 3635–3637. https://doi.org/10.1200/JCO.2017.74.6032. 
93
 Loprinzi, P.D., Lee, H., 2014. Rationale for promoting physical activity among cancer survivors: literature review and 
epidemiologic examination. Oncol. Nurs. Forum 41 (2), 117–125. https://doi.org/10.1188/14.ONF.117-125. 
94
 Gillis, C.R., Hole, D.J., 1996. Survival outcome of care by specialist surgeons in breast cancer: a study of 3786 patients in the 
west of Scotland. BMJ 312 (7024), 145. https://doi.org/10.1136/bmj.312.7024.145.  
95
 Skinner, A.K., Helsper, J.T., Deapen, D., Ye, W., Sposto, R., 2003. Breast cancer: Do specialists make a difference? Ann. 
Surg. Oncol. 10 (6), 606–615. https://doi.org/10.1245/ASO.2003.06.017.  
96
 Gooiker, G.A., van Gijn, W., Post, P.N., van de Velde, C.J., Tollenaar, R.A., Wouters, M.W., 2010. A systematic review and 
meta-analysis of the volume-outcome relationship in the surgical treatment of breast cancer. Are breast cancer patients better 
off with a high volume provider? Eur. J. Surg. Oncol. 36 Suppl 1, S27–S35. https://doi.org/10.1016/j.ejso.2010.06.024. 
97
 de Camargo Cancela, M., Comber, H., Sharp, L., 2013. Hospital and surgeon caseload are associated with risk of re-
operation following breast-conserving surgery. Breast Cancer Res. Treat. 140 (3), 535–544. https://doi.org/10.1007/s10549-013-
2652-5. 
98
 Greenup, R.A., Obeng-Gyasi, S., Thomas, S., Houck, K., Lane, W.O., Blitzblau, R.C., et al., 2018. The effect of hospital 
volume on breast cancer mortality. Ann. Surg. 267 (2), 375–381. https://doi.org/10.1097/SLA.0000000000002095. 
99
 Kesson, E.M., Allardice, G.M., George, W.D., Burns, H.J., Morrison, D.S., 2012. Effects of multidisciplinary team working on 
breast cancer survival: retrospective, comparative, interventional cohort study of 13,722 women. BMJ 344, e2718. 
https://doi.org/10.1136/bmj.e2718. 
100
 Kung, P.-T., Tsai, W.-C., 2014. Effects of multidisciplinary care on survival of breast cancer: Results from a national cohort 
study. 50 Suppl 4, e69. https://doi.org/10.1016/j.ejca.2014.03.257. 
101
 Foster, T.J., Bouchard-Fortier, A., Olivotto, I.A., Quan, M.L., 2016. Effect of multidisciplinary case conferences on physician 
decision making: breast diagnostic rounds. Cureus 8 (11), e895. https://doi.org/10.7759/cureus.895. 
102
 Newman, E.A., Guest, A.B., Helvie, M.A., Roubidoux, M.A., Chang, A.E., Kleer, C.G., et al., 2006. Changes in surgical 
management resulting from case review at a breast cancer multidisciplinary tumor board. Cancer 107 (10), 2346–2351. 
https://doi.org/10.1002/cncr.22266. 
103
 Holleczek, B., Brenner, H., 2014. Provision of breast cancer care and survival in Germany – results from a population-based 
high resolution study from Saarland. BMC Cancer 14, 757. https://doi.org/10.1186/1471-2407-14-757.  
104
 Leff, D.R., Ho, C., Thomas, H., Daniels, R., Side, L., Lambert, F., et al., 2015. A multidisciplinary team approach minimises 
prophylactic mastectomy rates. Eur. J. Surg. Oncol. 41 (8), 1005–1012. https://doi.org/10.1016/j.ejso.2015.02.017. 
105
 Saini, K.S., Taylor, C, Ramirez, A.J.,  Palmieri, C., Gunnarsson, U., Schmoll, H.J., et al., 2012. Role of the multidisciplinary 
team in breast cancer management: results from a large international survey involving 39 countries. Ann. Oncol. 23 (94), 853–
859. https://doi.org/10.1093/annonc/mdr352. 
106
 Taylor, C., Shewbridge, A., Harris, J., Green, J.S., 2013. Benefits of multidisciplinary teamwork in the management of breast 
cancer. Breast Cancer (Dove Med Press) 5, 79–85. https://doi.org/10.2147/BCTT.S35581. 
107
 Wallwiener, M., Brucker, S.Y., Wallwiener, D., 2012. Multidisciplinary breast centres in Germany: a review and update of 
quality assurance through benchmarking and certification. Arch. Gynecol. Obstet. 285 (6), 1671–1683. 
https://doi.org/10.1007/s00404-011-2212-3. 
108
 Köster, C., Heller, G., Wrede, S., König, T., Handstein, S., Szecsenyi, J., 2015. Case numbers and process quality 
in breast surgery in Germany: a retrospective analysis of over 150,000 patients from 2013 to 2014. Dtsch. Arztebl. Int. 112 (35–
36), 585–592. 10.3238/arztebl.2015.0585. 
109
 National Institute for Health and Care Excellence (NICE). Early and locally advanced breast cancer overview. 
https://pathways.nice.org.uk/pathways/early-and-locally-advanced-breast-cancer.  
110
 National Institute for Health and Care Excellence (NICE). Advanced breast cancer overview. 
https://pathways.nice.org.uk/pathways/advanced-breast-cancer. 
111
 Cancer Council Australia. Optimal cancer care pathways. https://www.cancer.org.au/health-professionals/optimal-cancer-
care-pathways.html. 
112
 Pittathankal, A., Davidson, T., 2010. Care pathways for patients with breast cancer. Trends Urology, Gynecol. Sexual Health 
15 (2),10–13. https://doi.org/10.1002/tre.144. 
113
 Bramesfeld, A., Ambrosio, M., Bocchi, G., Deandrea, S., Dimitrova, N., Saz-Parkinson, Z., et al., 2017. When science and 
policy collaborate for health. European Commission Initiative on Breast Cancer. Conference report by the Joint Research 
Centre (JRC). http://publications.jrc.ec.europa.eu/repository/bitstream/JRC106915/ecibc_plenary_2017_final_report.pdf. 
114
 German Cancer Society, 2018. Annual Report 2018 of the Certified Breast Cancer Centres (BCCs). Audit year 2017 / 
indicator year 2016. http://www.ecc-cert.org/fileadmin/user_upload/Annual_Report_Breast_2018.pdf. 
 
Version 8 November (final) 2019 
 
35 
 
                                                                                                                                                        
115
 Wind, A., Rajan, A., van Harten, W.H., 2016. Quality assessments for cancer centers in the European Union. BMC Health 
Serv. Res. 16, 474. https://doi.org/10.1186/s12913-016-1738-2. 
116
 National Institute for Health and Care Excellence (NICE). Breast cancer. Quality standard [QS12]. 
https://www.nice.org.uk/guidance/qs12. 
117
 van Bommel, A.C., Spronk, P.E., Vrancken Peeters, M.T., Jager, A., Lobbes, M., Maduro, J.H., et al., 2017. Clinical auditing 
as an instrument for quality improvement in breast cancer care in the Netherlands: The national NABON Breast Cancer Audit. J. 
Surg. Oncol. 115 (3), 243–249. 10.1002/jso.24516. 
118
 Benstead, K., Turhal, N.S., O’Higgins, N., Wyld, L., Czarnecka-Operacz, M., Gollnick, H., et al., 2017. Multidisciplinary 
training of cancer specialists in Europe. Eur. J. Cancer 83, 1–8. https://doi.org/10.1016/j.ejca.2017.05.043. 
119
 Montagna, G., Anderson, D., Bochenek-Cibor, J., Bozovic-Spasojevic, I., Campos, C., Cavallero, S., et al., 2019. How to 
become a breast cancer specialist in 2018: The point of view of the second cohort of the Certificate of Competence 
in Breast Cancer (CCB2). Breast 43, 18–21. https://doi.org/10.1016/j.breast.2018.10.006. 
120
 Rubio, I.T., Wyld, L., Esgueva, A., Kovacs, T., Cardoso, M.J., Leidenius, M., et al., 2019. Variability in breast cancer surgery 
training across Europe: an ESSO-EUSOMA international survey. Eur. J. Surg. Oncol. 45 (4), 567–572. 
https://doi.org/10.1016/j.ejso.2019.01.003. 



 
